EP3415182A1 - Zirconium phosphate disinfection recharging and conditioning - Google Patents
Zirconium phosphate disinfection recharging and conditioning Download PDFInfo
- Publication number
- EP3415182A1 EP3415182A1 EP18177673.3A EP18177673A EP3415182A1 EP 3415182 A1 EP3415182 A1 EP 3415182A1 EP 18177673 A EP18177673 A EP 18177673A EP 3415182 A1 EP3415182 A1 EP 3415182A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- zirconium phosphate
- sorbent module
- solution
- phosphate sorbent
- flowing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910000166 zirconium phosphate Inorganic materials 0.000 title claims abstract description 292
- LEHFSLREWWMLPU-UHFFFAOYSA-B zirconium(4+);tetraphosphate Chemical compound [Zr+4].[Zr+4].[Zr+4].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LEHFSLREWWMLPU-UHFFFAOYSA-B 0.000 title claims abstract description 292
- 230000003750 conditioning effect Effects 0.000 title abstract description 16
- 238000004659 sterilization and disinfection Methods 0.000 title description 22
- 239000002594 sorbent Substances 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 76
- 239000000243 solution Substances 0.000 claims description 308
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 170
- 239000012267 brine Substances 0.000 claims description 159
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims description 159
- 239000000645 desinfectant Substances 0.000 claims description 142
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 119
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 87
- 229910001868 water Inorganic materials 0.000 claims description 84
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 54
- 239000000203 mixture Substances 0.000 claims description 51
- 239000012530 fluid Substances 0.000 claims description 35
- 239000001632 sodium acetate Substances 0.000 claims description 30
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 27
- 239000011780 sodium chloride Substances 0.000 claims description 27
- 235000017281 sodium acetate Nutrition 0.000 claims description 26
- 230000003068 static effect Effects 0.000 claims description 25
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 238000010438 heat treatment Methods 0.000 claims description 10
- 230000000249 desinfective effect Effects 0.000 abstract description 13
- 238000000502 dialysis Methods 0.000 abstract description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 46
- 239000002253 acid Substances 0.000 description 21
- 159000000000 sodium salts Chemical class 0.000 description 15
- 239000000126 substance Substances 0.000 description 7
- 239000011800 void material Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- -1 ammonium ions Chemical class 0.000 description 4
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000017454 sodium diacetate Nutrition 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 238000005297 material degradation process Methods 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/168—Sterilisation or cleaning before or after use
- A61M1/169—Sterilisation or cleaning before or after use using chemical substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1694—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid
- A61M1/1696—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid with dialysate regeneration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/0203—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04
- B01J20/0211—Compounds of Ti, Zr, Hf
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
- B01J20/0203—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04
- B01J20/0274—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of metals not provided for in B01J20/04 characterised by the type of anion
- B01J20/0292—Phosphates of compounds other than those provided for in B01J20/048
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/34—Regenerating or reactivating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/34—Regenerating or reactivating
- B01J20/3433—Regenerating or reactivating of sorbents or filter aids other than those covered by B01J20/3408 - B01J20/3425
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/34—Regenerating or reactivating
- B01J20/345—Regenerating or reactivating using a particular desorbing compound or mixture
- B01J20/3475—Regenerating or reactivating using a particular desorbing compound or mixture in the liquid phase
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/34—Regenerating or reactivating
- B01J20/3483—Regenerating or reactivating by thermal treatment not covered by groups B01J20/3441 - B01J20/3475, e.g. by heating or cooling
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2220/00—Aspects relating to sorbent materials
- B01J2220/50—Aspects relating to the use of sorbent or filter aid materials
- B01J2220/62—In a cartridge
Definitions
- the invention relates to systems and methods for disinfecting, recharging, and conditioning zirconium phosphate in a reusable sorbent module.
- the systems and methods provide for reuse of a zirconium phosphate sorbent module after dialysis.
- Zirconium phosphate containing sorbent cartridges are used in dialysis to remove ammonium, potassium, calcium, and magnesium ions from dialysate, allowing the dialysate to be reused.
- Known systems require zirconium phosphate to be removed from a sorbent cartridge, transported to a reprocessor, treated, and placed into a new sorbent cartridge, increasing costs and waste associated with reuse of zirconium phosphate.
- Known systems and methods also cannot reuse a zirconium phosphate sorbent module by concurrently disinfecting the zirconium phosphate to reduce the microbial load to acceptable levels, recovering the capacity of the zirconium phosphate, and conditioning the zirconium phosphate to an appropriate chemical state for dialysis.
- the first aspect of the invention relates to a method of recharging zirconium phosphate in a zirconium phosphate sorbent module.
- the method can include flowing a disinfectant solution through the zirconium phosphate sorbent module; and flowing a brine solution through the zirconium phosphate sorbent module.
- the method can include the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
- the disinfectant solution can be a peracetic acid solution and the brine solution can contain acetic acid, sodium acetate, and sodium chloride.
- the brine solution can contain between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- the disinfection solution can contain between 0.1 to 3wt% peracetic acid.
- the disinfection solution can contain between 0.1 to 3wt% peracetic acid and between 0.1 to 15wt% acetic acid.
- the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- the mixture of disinfectant solution and brine solution can be maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.
- the mixture of disinfectant solution and brine solution can be maintained at room temperature for a set period of time, and then heated for a set period of time.
- the mixture of disinfectant solution and brine solution can have between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- the step of flowing a disinfectant solution through the zirconium phosphate sorbent module can include flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.
- the step of flowing a brine solution through the zirconium phosphate sorbent module can include flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
- the brine solution can be flowed through the zirconium phosphate sorbent module after the peracetic acid is flowed through the zirconium phosphate sorbent module.
- the peracetic acid solution can be flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.
- the method can include the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module.
- the brine solution can be heated to a temperature up to 100 °C.
- the method can include flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing the mixture from a combined disinfectant solution and brine solution source.
- the method can include rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.
- the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module can include flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.
- the method can include holding the disinfectant solution in the zirconium phosphate sorbent module.
- the disinfectant solution can be held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
- the method can include flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.
- the method can include intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.
- the method can include rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.
- the brine solution, the water, and the disinfectant solution can be flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
- the zirconium phosphate recharging flow path can include (i) a water source and a combined disinfectant solution and brine solution source; (ii) a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module; (iii) at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; and; (iv) a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet.
- the combined disinfectant solution and brine solution source can contain between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- the zirconium phosphate recharging flow path can include a second pump.
- the zirconium phosphate recharging flow path can include a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.
- an element means one element or over one element.
- acetic acid refers to CH 3 CO 2 H in an aqueous solution.
- a “brine solution” is a solution containing sodium chloride, an acid, and the sodium salt of the acid.
- combined disinfectant solution and brine solution source refers to any source of a fluid containing both a disinfectant and a brine solution.
- a “concentrated” solution refers to a solution having at least one solute in a higher concentration than intended for use.
- a “dilute” solution refers to a concentrated solution after addition of a solvent to lower the solute concentration.
- direction opposite to a flow direction during therapy refers to a direction of fluid flow through a component that is in reserver to an initial flow direction, or 180° to the initial direction of fluid flow, through the component during dialysis therapy.
- fectant solution refers to any solution capable of destroying or removing bacterial contaminants from a reusable sorbent module.
- flow rate refers to a volume of fluid moved in a flow path in a given period of time.
- a "fluid” is a liquid substance optionally having a combination of gas and liquid phases in the fluid.
- a liquid as used herein, can therefore also have a mixture of gas and liquid phases of matter.
- fluidly connectable refers to the ability of providing for the passage of fluid, gas, or a combination thereof, from one point to another point.
- the two points can be within or between any one or more of compartments, modules, systems, components, and rechargers, all of any type.
- the connection can optionally be disconnected and then reconnected.
- the term “generate” refers to creating a fluid with a specified concentration, pH, temperature, and/or volume from one or more fluid sources.
- heating or to “heat” refers to raising the temperature of a material.
- holding a disinfectant solution or to "hold a disinfectant solution” refers to adding a disinfectant solution to a component without immediate removal of the disinfectant solution.
- holding a disinfectant solution can also refer to flowing a disinfectant solution through the component at a low flow rate or an intermittent flow rate.
- the term "maintained at room temperature” or to “maintain at room temperature” refers to keeping a substance from increasing or decreasing in temperature substantially from room temperature.
- mixture refers to a fluid having at least two components, the two components combined to form a substantially homogeneous substance.
- peracetic acid refers to CH 3 CO 3 H in an aqueous solution.
- peracetic acid solution refers to a solution of peracetic acid, acetic acid and hydrogen peroxide
- pump refers to any device that causes the movement of fluids, gases, or combinations thereof, by applying suction or pressure.
- Recharging refers to treating a sorbent material to restore the functional capacity of the sorbent material to put the sorbent material back into a condition for reuse or use in a new dialysis session.
- the total mass, weight and/or amount of "rechargeable” sorbent materials remain the same.
- the total mass, weight and/or amount of "rechargeable” sorbent materials change.
- the recharging process may involve exchanging ions bound to the sorbent material with different ions, which in some instances may increase or decrease the total mass of the system. However, the total amount of the sorbent material will in some instances be unchanged by the recharging process. Upon a sorbent material undergoing "recharging,” the sorbent material can then be said to be “recharged.”
- heating or to “rinse” refers to flowing water through a component to remove substances from the component.
- room temperature refers to the ambient temperature in an environment without additional heating or cooling. In general, room temperature can be considered between 15 and 30°C.
- set period of time refers to a specific amount of time elapsed between two events.
- sodium acetate refers to CH 3 CO 2 Na in an aqueous solution.
- sodium chloride refers to NaCl.
- a "sorbent cartridge module” or “sorbent module” means a discreet component of a sorbent cartridge. Multiple sorbent cartridge modules can be fitted together to form a sorbent cartridge of two, three, or more sorbent cartridge modules. In some embodiments, a single sorbent cartridge module can contain all of the necessary materials for dialysis. In such cases, the sorbent cartridge module can be a "sorbent cartridge.”
- a “static mixer” is a component configured to receive fluids from one or multiple sources and to mix the fluids together.
- the static mixer may include components that agitate the fluids to further mixing.
- void volume refers to a volume contained in a cartridge, not including a sorbent or any other material, through which liquid can flow.
- void volume can also refer to the volume of a cartridge or container available for a liquid or gas to fill the cartridge or container.
- water refers to H 2 O in a liquid state.
- Water can refer to portable water, drinking water, purified water, deionized water, tap water, or a solution containing one or more solutes dissolved in thewater.
- the water shall not be limited to any specific purity, disinfection time, toxicity, microbial load, or any other indicator of water quality.
- a “water source” is a fluid source from which water can be obtained.
- Zero phosphate is a sorbent material that removes cations from a fluid, exchanging the removed cations for different cations.
- zirconium phosphate effluent line is a fluid passageway, tube, or path of any kind into which fluid exiting a zirconium phosphate sorbent module will flow.
- zirconium phosphate module or "zirconium phosphate sorbent module” is a sorbent module containing zirconium phosphate.
- a "zirconium phosphate sorbent module inlet” is a connector through which a fluid, slurry, or aqueous solution can enter a zirconium phosphate sorbent module.
- a "zirconium phosphate sorbent module outlet” is a connector through which a fluid, slurry, or aqueous solution can exit a zirconium phosphate sorbent module.
- a "zirconium phosphate recharging flow path" is a path through which fluid can travel while recharging zirconium phosphate in a reusable zirconium phosphate sorbent module.
- FIG. 1 is a flow chart illustrating a method for disinfecting, recharging, and conditioning zirconium phosphate.
- the cartridge must be disinfected to reduce the microbial load to acceptable levels, illustrated as disinfection steps 103-105; the capacity of the zirconium phosphate must be recovered, illustrated as recharging step 106-; and the zirconium phosphate must be returned to an appropriate chemical state, or conditioned, which occurs during step 106-107.
- the method of disinfecting the zirconium phosphate in a zirconium phosphate sorbent module can begin in step 101.
- the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy.
- the spent dialysate can have proteinaceous and other compounds that interact with the disinfectant used in subsequent steps. Rinsing the zirconium phosphate sorbent module with water removes the proteinaceous compounds.
- any volume of water sufficient to remove the spent dialysate can be flowed through the zirconium phosphate sorbent module in step 102, including between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L. In a preferred embodiment, about 1.0 L of water is flowed through the zirconium phosphate sorbent module in rinsing step 102.
- the rinse water can be flowed through the zirconium phosphate sorbent module at any temperature. In certain embodiments, the rinse water can be heated to aid in removal of spent dialysate or for pre-heating the zirconium phosphate sorbent module.
- Pre-heating the zirconium phosphate sorbent module can increase efficiency where the zirconium phosphate sorbent module may have been stored at low temperatures, such as 10 °C or less.
- the rinse water can be heated to any temperature between 20 and 100 °C.
- the zirconium phosphate sorbent module can be filled with a disinfectant solution in step 103.
- An aqueous peracetic acid solution can be the disinfectant solution.
- the peracetic acid solution can have any concentration of peracetic acid sufficient to disinfect the zirconium phosphate sorbent module, including between 0.1 and 5 wt%. In a preferred embodiment, the peracetic acid solution is 1 wt% in water.
- the volume of peracetic acid flowed into the zirconium phosphate sorbent module can be enough to fill the zirconium phosphate sorbent module, and can be between 100% to 200% or more of the void volume of the zirconium phosphate sorbent module. In a preferred embodiment, a volume of peracetic acid solution flowed into the zirconium phosphate sorbent module is 150% of the module void volume. With a 1.2 L zirconium phosphate sorbent module, 1.8 L of peracetic acid solution can be flowed into the module in step 103.
- the peracetic acid solutions can be mixtures of peracetic acid, acetic acid and hydrogen peroxide.
- peracetic acid is the result of mixing acetic acid and hydrogen peroxide together, resulting in the generation of peracetic acid in equilibrium with the acetic acid and hydrogen peroxide.
- peracetic acid solution available, which vary in the concentration of peracetic acid, acetic acid, and hydrogen peroxide.
- the disinfectant solution can be a combined peracetic acid and acetic acid solution, which increases the effectiveness of the disinfection as compared to peracetic acid alone.
- the combined disinfectant and acid solution can contain between 0.1 and 3 wt% peracetic acid and 0.1 to 15 wt% acetic acid.
- hydrogen peroxide can be added to the peracetic acid, which increases the effectiveness of the disinfection as compared to peracetic acid alone.
- the addition of hydrogen peroxide can drive the equilibrium of peracetic acid, hydrogen peroxide, and acetic acid towards generation of peracetic acid as the initial peracetic acid is consumed.
- both peracetic acid and hydrogen peroxide can be used as disinfectants alone.
- Both peracetic acid and hydrogen peroxide operate by oxidation, with each having an oxidation potential of 1.8 electron volts. Adding hydrogen peroxide to the peracetic acid solution can increase the total oxidation potential of the mixture, resulting in a more potent disinfectant.
- Chemical formulations including mixtures of peracetic acid and hydrogen peroxide are known.
- the mixtures can be clear, colorless liquids that are miscible with water.
- the mixtures can be oxidizing agents and disinfectants with a pungent odor, having peracetic acid, acetic acid, and hydrogen peroxide in equilibrium. Thermal decomposition of the mixtures occurs at temperatures above 60 °C.
- Known compositions of peracetic acid and hydrogen peroxide solutions are available from Evonik, a German corporation.
- peracetic acid and hydrogen peroxide solutions examples include PERACLEAN® 5 having 5% peracetic acid and 26% hydrogen peroxide, PERACLEAN® 10 having 10% peracetic acid and 20% hydrogen peroxide, PERACLEAN® 15 having 15% peracetic acid and 21% hydrogen peroxide, PERACLEAN® 35 having 35% peracetic acid and 7% hydrogen peroxide, and PERACLEAN® 40 having 39% peracetic acid and 4% hydrogen peroxide.
- concentration of peracetic acid in the mixture is decreased, additional hydrogen peroxide can be added to increase effectiveness of the mixture.
- the formulations, or any other source of peracetic acid and hydrogen peroxide can be diluted to obtain a solution with desired concentrations of peracetic acid and hydrogen peroxide.
- the disinfectant solution can be held in the zirconium phosphate sorbent module for a sufficient length of time to ensure complete disinfection of the zirconium phosphate sorbent module.
- the hold time can be any length of time, including between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
- the length of the hold time can depend on the temperature of the zirconium phosphate sorbent module, and in a preferred embodiment the hold time can be 15 minutes at 22 °C.
- the disinfectant solution can be heated in steps 103-104 to a temperature higher than 22 °C, which increases the efficiency of disinfection.
- the disinfectant can be heated to any temperature, including between 22 °C and 100 °C, between 22 °C and 50 °C, between 22 °C and 35 C, between 30 °C and 50 °C, between 35 °C and 65 °C, between 50 °C and 75 °C, or between 60 °C and 100 °C.
- a low flow rate of fluid through the zirconium phosphate sorbent module can be used to prevent pressure build up in the cartridge resulting from the degradation of peracetic acid.
- the low flow rate can vary from 1 to 20 ml/min.
- the low flow rate can have an on/off flow profile by intermittently switching the flow rate on and off while holding the disinfectant solution.
- the flow rate during the disinfectant hold can be set as 55ml/ min for 15 seconds and 0 ml/min for 45 seconds.
- the hold flow rate is 15 cycles of 55 ml/min for 15 seconds and 0-ml/min for 45 seconds.
- the zirconium phosphate module can be rinsed with water, allowing a buffer of water to be present between the peracetic acid solution and the subsequent brine solution.
- Step 105 is optional, and the method can proceed without rinsing between the peracetic acid step 104 and the brine step 106.
- the volume of water used can vary between 0 and 1.0 L or more.
- step 105 is omitted.
- the zirconium phosphate module can be rinsed if material degradation to the cartridge housing or other components is detected. Material degradation may be an issue if the disinfectant used is a heated mixture of peracetic acid and acetic acid, or a mixture of peracetic acid and brine at temperatures around 80 °C.
- a brine solution can be flowed through the zirconium phosphate sorbent module to recharge the zirconium phosphate.
- the brine solution can include an aqueous solution of sodium chloride, and acid, and the sodium salt of the acid.
- the brine solution provides additional disinfection of the zirconium phosphate; recovers the capacity of the zirconium phosphate by removing ammonium, potassium, calcium, and magnesium ions in exchange for sodium and hydrogen ions; and leaves the zirconium phosphate at the desired pH, or in the proper/desired sodium to hydrogen ion ratio for dialysis.
- FIG. 1 illustrates flowing the brine solution through the zirconium phosphate sorbent module in step 106 after flowing the disinfectant solution through the zirconium phosphate sorbent module in step 104, the order can be reversed, with the brine solution flowed through the zirconium phosphate module first, followed by the disinfectant solution.
- Flowing the disinfectant solution through the zirconium phosphate sorbent module after the brine solution can reduce the risk of the brine solution contaminating the cartridge.
- the disinfectant solution can be kept in the zirconium phosphate sorbent module during storage, preventing microbial growth in the zirconium phosphate sorbent module during storage.
- the brine solution includes sodium chloride, acetic acid, and sodium acetate.
- the brine solution can be a glycolic/glycolate solution, a citric acid/citrate solution, a propionate/propionic acid solution, monobasic phosphate, or any combination thereof.
- the relative ratios of the acid and sodium salt of the acid in the brine solution can be varied depending on the desired zirconium phosphate pH.
- the concentration of sodium chloride can vary between 0 and 5.0 M, the concentration of acetic acid can vary between 0.1 and 2.0 M, and the concentration of sodium acetate can vary between 0.1 and 2 M, where the upper concentration limits are only limited by solubility.
- the sodium chloride can be omitted in certain embodiments, and the zirconium phosphate sorbent module can be recharged with an acid and the sodium salt of the acid.
- the sodium salt of the acid can provide sodium ions and the acid can provide the hydrogen ions for recharging.
- the upper limit of the sodium salt and acid concentration is based on the solubility of the sodium salt and acid, and can depend on the type of sodium salt used and the acid concentration used.
- the brine solution contains about 4.854 M sodium chloride, 0.350 M sodium acetate, and 0.350 M acetic acid.
- Table 1 provides non-limiting examples of brine solutions and the resulting initial therapy zirconium phosphate effluent pH. In each case, the solution was heated to 80°C prior to use. As shown in Table 1, a higher ratio of sodium acetate to acetic acid results in a higher solution pH, and therefore a higher initial therapy zirconium phosphate effluent pH.
- the relative amounts of acid, base, and sodium salt can be set to generate a brine solution resulting in a desired initial effluent pH.
- Each of the solutions in Table 1 are combinations of sodium chloride, sodium acetate, and acetic acid.
- One of skill in the art will understand that other combinations can be used in place of sodium acetate and acetic acid, including sodium diacetate.
- the sodium diacetate can be mixed with sodium acetate or acetic acid to result in a brine solution having a desired pH.
- Sodium diacetate and sodium acetate are solids, which may be easier to ship and store.
- the sodium diacetate and/or sodium acetate can be shipped and stored as a dry powder, eliminating the need to ship and handle acetic acid.
- the brine solution can optionally be heated. Heating the brine solution increases the efficiency of the recharging process.
- the brine solution can be heated to any temperature between 22 and 100°C, including between 22 and 40°C, between 22 and 60°C, between 35 and 50°C, between 45 and 70°C, between 55 and 85°C, between 60 and 90°C, between 75 and 85°C, or between 70 and 100°C.
- the brine solution is heated to about 80°C during step 106.
- the brine solution can be used at lower temperatures with a decrease in efficiency.
- the volume of brine solution to recharge the zirconium phosphate depends on the cations bound to the zirconium phosphate during therapy, and the size of the zirconium phosphate sorbent module, the temperature of the brine solution, and the concentrations of sodium chloride, acid, and sodium salt of the acid used in the brine solution.
- the volume of brine is 6.2L for a zirconium phosphate sorbent module containing 2.69kg of ZP with a capacity of 1 mEq cation per gram of ZP.
- the zirconium phosphate sorbent module can be rinsed in step 107 by flowing water through the zirconium phosphate sorbent module.
- the rinsing is necessary to remove the brine solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session.
- the rinse water volume can vary from 100% to 500% of the cartridge void volume. In a preferred embodiment, the volume of rinse water is about 333% of the cartridge void volume, or 4L for a zirconium phosphate sorbent module with a 1.2L void volume.
- the rinsing step 107 can occur during recharging of the zirconium phosphate sorbent module, or the zirconium phosphate sorbent module can be rinsed in the dialysis system just prior to use. Rinsing the zirconium phosphate sorbent module just prior to use allows the disinfectant solution, if the disinfectant step is performed after the brine step, to remain in the zirconium phosphate sorbent module during storage, reducing microbial growth.
- the method can end in step 108, with a zirconium phosphate sorbent module in condition for reuse in dialysis.
- the zirconium phosphate module can be fully or partially drained after recharging and conditioning for storage, which decreases the weight and exposure to water during storage.
- the direction of flow of brine through the zirconium phosphate sorbent module during step 106 can be in a direction opposite to a flow direction during therapy.
- spent dialysate enters the bottom of the module, flows upwards against gravity, and exits the top of the cartridge.
- the brine can enter the zirconium phosphate sorbent module at the top and exit through the bottom, flowing with gravity.
- the spent dialysate flow direction during therapy can be downward, and the brine can flow upwardly through the zirconium phosphate sorbent module during recharging.
- the rinse and disinfection flow direction during steps 102-105 and 107 can be either the same or opposite to the flow direction during therapy.
- the direction of flow of brine during recharging can be the same as the flow direction during therapy, however, flowing brine through the zirconium phosphate module in the same direction as flow during therapy may require additional brine volume for recharging.
- the rinse and disinfection flow direction is the same direction as the brine flow direction.
- FIG. 2 illustrates an alternative embodiment of the disinfection, recharging, and conditioning of zirconium phosphate.
- the method can start in step 201.
- the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy.
- a mixture of disinfectant solution and brine can be flowed through the zirconium phosphate sorbent module.
- the disinfectant solution can be added to the brine, and the process for recharging, disinfecting, and conditioning the zirconium phosphate sorbent module can be similar to the process illustrated in FIG. 1 , allowing disinfection, capacity recovery, and conditioning in one step.
- the mixture of disinfectant solution and brine disinfects and recharges the zirconium phosphate in a single step, as opposed to separate steps as illustrated in FIG. 1 .
- the concentrations of peracetic acid, sodium chloride, sodium acetate, and acetic acid in the mixture can be the same as the individual solutions shown in FIG. 1 .
- the mixture of brine and peracetic acid may help stabilize the peracetic acid in the disinfectant solution because the presence of the acetate buffer keeps the peracetic acid/acetic acid equilibrium shifted to the peracetic acid side.
- the mixture of peracetic acid and brine can be held in the zirconium phosphate sorbent module for any length of time sufficient to ensure complete disinfection or alternatively, the mixture of peracetic acid and brine can be continuously flowed through the zirconium phosphate sorbent module.
- the mixture of peracetic acid and brine is heated to about 80°C in step 203, however the solutions may alternatively be at a lower, unheated temperature, such as room temperature.
- the mixture of peracetic acid and brine can be heated to any temperature between 22 and 100°C, including between 22 and 40°C, between 22 and 60°C, between 35 and 50°C, between 45 and 70°C, between 55 and 85°C, between 60 and 90°C, between 75 and 85°C, or between 80 and 100°C.
- the mixture of peracetic acid and brine can be kept at room temperature for a set period of time to ensure complete disinfection, and then heated for a set period of time to increase the efficiency of the recharging process.
- the mixture of peracetic acid and brine solution can be maintained at room temperature for 5-30 minutes, and then subsequently heated.
- step 204 the zirconium phosphate sorbent module can be rinsed by flowing water through the zirconium phosphate sorbent module to remove the brine and peracetic acid solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session.
- the method can end in step 205 with a zirconium phosphate sorbent module in condition for reuse in dialysis.
- FIG. 3 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconium phosphate sorbent module 302.
- a zirconium phosphate sorbent module 302 can connect to the zirconium phosphate recharging flow path 301 through zirconium phosphate sorbent module inlet 303 and zirconium phosphate sorbent module outlet 304.
- a zirconium phosphate effluent line 311 can be fluidly connected to the zirconium phosphate sorbent module outlet 304 for removal of solutions after the solutions pass through the zirconium phosphate sorbent module 302.
- Pump 307 provides a driving force for flowing fluids through the zirconium phosphate recharging flow path 301.
- a brine source 305 containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid is fluidly connected to the zirconium phosphate recharging flow path 301.
- Disinfectant source 306 can contain a disinfectant solution, such as peracetic acid.
- Water source 310 is also fluidly connected to the zirconium phosphate recharging flow path 301.
- the water source 310 can contain any water as defined herein, including deionized water. The water can be obtained from a tap such as a faucet or from any other readily available source in a home setting.
- Valve 308 controls the movement of fluid through the zirconium phosphate recharging flow path 301 and zirconium phosphate sorbent module 302.
- a static mixer 309 can optionally be included to ensure complete mixing of solutions prior to entering the zirconium phosphate sorbent module 302.
- the static mixer 309 ensures that the peracetic acid and brine are mixed to generate a dilute mixture of brine and peracetic acid for simultaneous recharging and disinfection.
- the brine source 305, disinfectant source 306, and water source 310 can be connected to the zirconium phosphate recharging flow path 301 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphate recharging flow path 301.
- the zirconium phosphate recharging flow path 301 can flow solutions through the zirconium phosphate sorbent module 302 in a sequential order or simultaneously. As illustrated in FIG. 1 , the zirconium phosphate recharging flow path 301 can flow water, disinfectant, brine, and water again through the zirconium phosphate sorbent module 302 sequentially. The zirconium phosphate recharging flow path 301 can flow water through the zirconium phosphate sorbent module 302, followed by simultaneously flowing peracetic acid and brine through the zirconium phosphate sorbent module 302 as illustrated in FIG. 2 .
- the solutions in the brine source 305 and disinfectant source 306 can be any concentration, including the concentrations shown in FIG.'s 1-2.
- the solutions in brine source 305 and/or disinfectant source 306 can be concentrated solutions.
- the brine solution can have sodium chloride, acid, and sodium salt of the acid at concentrations higher than that to be used in recharging the zirconium phosphate sorbent module 302.
- the brine solution and water can be simultaneously flowed to static mixer 309 to dilute the concentrated brine solution in the recharging steps generating a dilute brine solution usable for recharging the zirconium phosphate.
- a concentrated disinfectant solution and water can be simultaneously flowed to static mixer 309 to dilute the disinfectant solution during the disinfecting steps, generating a dilute disinfectant solution for disinfecting the zirconium phosphate.
- a heater and/or heat exchanger (not shown) can be included for heating the brine solution, the disinfectant solution, and/or the rinse water prior to flowing the solutions through the zirconium phosphate sorbent module 302.
- FIG. 4 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconium phosphate sorbent module 402 with a combined brine and disinfectant fluid, as illustrated in FIG. 2 .
- a zirconium phosphate sorbent module 402 can connect to the zirconium phosphate recharging flow path 401 through zirconium phosphate sorbent module inlet 403 and zirconium phosphate sorbent module outlet 404.
- a zirconium phosphate effluent line 410 can be fluidly connected to the zirconium phosphate sorbent module outlet 404 for removal of solutions after the solutions pass through the zirconium phosphate sorbent module 402.
- a combined disinfectant solution and brine solution source 405, containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid, and a disinfectant such as peracetic acid, can be fluidly connected to the zirconium phosphate recharging flow path 401.
- Water source 406 is also fluidly connected to the zirconium phosphate recharging flow path 401.
- Valve 408 controls the movement of fluid through the zirconium phosphate recharging flow path 401 and zirconium phosphate sorbent module 402.
- a static mixer 409 can optionally be included to ensure complete mixing of solutions prior to entering the zirconium phosphate sorbent module 402 and can generate a dilute solution from the combined disinfectant solution and brine solution source 405 when a concentrated solution is used.
- the combined disinfectant solution and brine solution source 405 and water source 406 can be connected to the zirconium phosphate recharging flow path 401 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphate recharging flow path 401.
- a heater and/or heat exchanger (not shown) can be included for heating the combined disinfectant solution and brine solution and/or the rinse water prior to flowing the solutions through the zirconium phosphate sorbent module 402.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
- This application claims the benefit of and priority to
U.S. Provisional Patent Application No. 62/519,933 filed June 15, 2017 - The invention relates to systems and methods for disinfecting, recharging, and conditioning zirconium phosphate in a reusable sorbent module. The systems and methods provide for reuse of a zirconium phosphate sorbent module after dialysis.
- Zirconium phosphate containing sorbent cartridges are used in dialysis to remove ammonium, potassium, calcium, and magnesium ions from dialysate, allowing the dialysate to be reused. Known systems require zirconium phosphate to be removed from a sorbent cartridge, transported to a reprocessor, treated, and placed into a new sorbent cartridge, increasing costs and waste associated with reuse of zirconium phosphate. Known systems and methods also cannot reuse a zirconium phosphate sorbent module by concurrently disinfecting the zirconium phosphate to reduce the microbial load to acceptable levels, recovering the capacity of the zirconium phosphate, and conditioning the zirconium phosphate to an appropriate chemical state for dialysis. Hence, there is a need for systems and methods that can quickly and effectively disinfect, recharge and condition zirconium phosphate in a reusable sorbent module. There is further a need for systems and methods optimized to carry out all three steps with the least amount of waste at reduced cost than known systems and methods.
- The first aspect of the invention relates to a method of recharging zirconium phosphate in a zirconium phosphate sorbent module. In any embodiment, the method can include flowing a disinfectant solution through the zirconium phosphate sorbent module; and flowing a brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the method can include the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the disinfectant solution can be a peracetic acid solution and the brine solution can contain acetic acid, sodium acetate, and sodium chloride.
- In any embodiment, the brine solution can contain between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- In any embodiment, the disinfection solution can contain between 0.1 to 3wt% peracetic acid.
- In any embodiment, the disinfection solution can contain between 0.1 to 3wt% peracetic acid and between 0.1 to 15wt% acetic acid.
- In any embodiment, the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.
- In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature for a set period of time, and then heated for a set period of time.
- In any embodiment, the mixture of disinfectant solution and brine solution can have between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- In any embodiment, the step of flowing a disinfectant solution through the zirconium phosphate sorbent module can include flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.
- In any embodiment, the step of flowing a brine solution through the zirconium phosphate sorbent module can include flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the brine solution can be flowed through the zirconium phosphate sorbent module after the peracetic acid is flowed through the zirconium phosphate sorbent module.
- In any embodiment, the peracetic acid solution can be flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.
- In any embodiment, the method can include the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the brine solution can be heated to a temperature up to 100 °C.
- In any embodiment, the method can include flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing the mixture from a combined disinfectant solution and brine solution source.
- In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.
- In any embodiment, the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module can include flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.
- In any embodiment, the method can include holding the disinfectant solution in the zirconium phosphate sorbent module.
- In any embodiment, the disinfectant solution can be held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
- In any embodiment, the method can include flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.
- In any embodiment, the method can include intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.
- In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.
- In any embodiment, the brine solution, the water, and the disinfectant solution can be flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
- The features disclosed as being part of the first aspect of the invention can be in the first aspect of the invention, either alone or in combination.
- The second aspect of the invention is drawn to a zirconium phosphate recharging flow path. In any embodiment, the zirconium phosphate recharging flow path can include (i) a water source and a combined disinfectant solution and brine solution source; (ii) a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module; (iii) at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; and; (iv) a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet.
- In any embodiment, the combined disinfectant solution and brine solution source can contain between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- In any embodiment, the zirconium phosphate recharging flow path can include a second pump.
- In any embodiment, the zirconium phosphate recharging flow path can include a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.
- The features disclosed as being part of the second aspect of the invention can be in the second aspect of the invention, either alone or in combination.
-
-
FIG. 1 is a flow chart of a method for disinfecting, recharging and conditioning zirconium phosphate. -
FIG. 2 is a flow chart of a method for disinfecting, recharging and conditioning zirconium phosphate with a combined disinfection and recharging solution. -
FIG. 3 is a flow path for disinfection, recharging and conditioning of zirconium phosphate in a reusable sorbent module. -
FIG. 4 is a flow path for disinfection, recharging and conditioning of zirconium phosphate using a combined disinfection and recharging solution. - Unless defined otherwise, all technical and scientific terms used generally have the same meaning as commonly understood by one of ordinary skill in the art.
- The articles "a" and "an" are used to refer to one or to over one (i.e., to at least one) of the grammatical object of the article. For example, "an element" means one element or over one element.
- The term "acetic acid" refers to CH3CO2H in an aqueous solution.
- A "brine solution" is a solution containing sodium chloride, an acid, and the sodium salt of the acid.
- The term "combined disinfectant solution and brine solution source" refers to any source of a fluid containing both a disinfectant and a brine solution.
- The term "comprising" includes, but is not limited to, whatever follows the word "comprising." Use of the term indicates the listed elements are required or mandatory but that other elements are optional and may be present.
- A "concentrated" solution refers to a solution having at least one solute in a higher concentration than intended for use.
- The term "consisting of' includes and is limited to whatever follows the phrase "consisting of." The phrase indicates the limited elements are required or mandatory and that no other elements may be present.
- The term "consisting essentially of' includes whatever follows the term "consisting essentially of' and additional elements, structures, acts or features that do not affect the basic operation of the apparatus, structure or method described.
- A "dilute" solution refers to a concentrated solution after addition of a solvent to lower the solute concentration.
- The term "direction opposite to a flow direction during therapy" refers to a direction of fluid flow through a component that is in reserver to an initial flow direction, or 180° to the initial direction of fluid flow, through the component during dialysis therapy.
- The term "disinfectant solution" refers to any solution capable of destroying or removing bacterial contaminants from a reusable sorbent module.
- The terms "flowing" or to "flow" "refer to the movement of a fluid, gas, or mixtures thereof.
- The term "flow rate" refers to a volume of fluid moved in a flow path in a given period of time.
- A "fluid" is a liquid substance optionally having a combination of gas and liquid phases in the fluid. Notably, a liquid, as used herein, can therefore also have a mixture of gas and liquid phases of matter.
- The term "fluidly connectable," "fluidly connect," "for fluid connection," and the like, refer to the ability of providing for the passage of fluid, gas, or a combination thereof, from one point to another point. The two points can be within or between any one or more of compartments, modules, systems, components, and rechargers, all of any type. The connection can optionally be disconnected and then reconnected.
- The term "generate" refers to creating a fluid with a specified concentration, pH, temperature, and/or volume from one or more fluid sources.
- The term "heating" or to "heat" refers to raising the temperature of a material.
- The term "holding a disinfectant solution" or to "hold a disinfectant solution" refers to adding a disinfectant solution to a component without immediate removal of the disinfectant solution. The term "holding a disinfectant solution" can also refer to flowing a disinfectant solution through the component at a low flow rate or an intermittent flow rate.
- The term "intermittently" refers to a process that starts and stops multiple times.
- The term "maintained at room temperature" or to "maintain at room temperature" refers to keeping a substance from increasing or decreasing in temperature substantially from room temperature.
- The term "mixture" refers to a fluid having at least two components, the two components combined to form a substantially homogeneous substance.
- The term "peracetic acid" refers to CH3CO3H in an aqueous solution.
- The term "peracetic acid solution" refers to a solution of peracetic acid, acetic acid and hydrogen peroxide
- The term "pump" refers to any device that causes the movement of fluids, gases, or combinations thereof, by applying suction or pressure.
- "Recharging" refers to treating a sorbent material to restore the functional capacity of the sorbent material to put the sorbent material back into a condition for reuse or use in a new dialysis session. In some instances, the total mass, weight and/or amount of "rechargeable" sorbent materials remain the same. In some instances, the total mass, weight and/or amount of "rechargeable" sorbent materials change. Without being limited to any one theory of invention, the recharging process may involve exchanging ions bound to the sorbent material with different ions, which in some instances may increase or decrease the total mass of the system. However, the total amount of the sorbent material will in some instances be unchanged by the recharging process. Upon a sorbent material undergoing "recharging," the sorbent material can then be said to be "recharged."
- The term "rinsing" or to "rinse" refers to flowing water through a component to remove substances from the component.
- The term "room temperature" refers to the ambient temperature in an environment without additional heating or cooling. In general, room temperature can be considered between 15 and 30°C.
- The term "set period of time" refers to a specific amount of time elapsed between two events.
- The term "sodium acetate" refers to CH3CO2Na in an aqueous solution.
- The term "sodium chloride" refers to NaCl.
- A "sorbent cartridge module" or "sorbent module" means a discreet component of a sorbent cartridge. Multiple sorbent cartridge modules can be fitted together to form a sorbent cartridge of two, three, or more sorbent cartridge modules. In some embodiments, a single sorbent cartridge module can contain all of the necessary materials for dialysis. In such cases, the sorbent cartridge module can be a "sorbent cartridge."
- A "static mixer" is a component configured to receive fluids from one or multiple sources and to mix the fluids together. The static mixer may include components that agitate the fluids to further mixing.
- The term "void volume" refers to a volume contained in a cartridge, not including a sorbent or any other material, through which liquid can flow. The term "void volume" can also refer to the volume of a cartridge or container available for a liquid or gas to fill the cartridge or container.
- The term "water," as used herein, refers to H2O in a liquid state. "Water" can refer to portable water, drinking water, purified water, deionized water, tap water, or a solution containing one or more solutes dissolved in thewater. The water shall not be limited to any specific purity, disinfection time, toxicity, microbial load, or any other indicator of water quality.
- A "water source" is a fluid source from which water can be obtained.
- "Zirconium phosphate" is a sorbent material that removes cations from a fluid, exchanging the removed cations for different cations.
- A "zirconium phosphate effluent line" is a fluid passageway, tube, or path of any kind into which fluid exiting a zirconium phosphate sorbent module will flow.
- A "zirconium phosphate module" or "zirconium phosphate sorbent module" is a sorbent module containing zirconium phosphate.
- A "zirconium phosphate sorbent module inlet" is a connector through which a fluid, slurry, or aqueous solution can enter a zirconium phosphate sorbent module.
- A "zirconium phosphate sorbent module outlet" is a connector through which a fluid, slurry, or aqueous solution can exit a zirconium phosphate sorbent module.
- A "zirconium phosphate recharging flow path" is a path through which fluid can travel while recharging zirconium phosphate in a reusable zirconium phosphate sorbent module. Zirconium Phosphate Recharging, Disinfection, and Conditioning
-
FIG. 1 is a flow chart illustrating a method for disinfecting, recharging, and conditioning zirconium phosphate. To reuse zirconium phosphate in dialysis, the method must achieve three steps. The cartridge must be disinfected to reduce the microbial load to acceptable levels, illustrated as disinfection steps 103-105; the capacity of the zirconium phosphate must be recovered, illustrated as recharging step 106-; and the zirconium phosphate must be returned to an appropriate chemical state, or conditioned, which occurs during step 106-107. - The method of disinfecting the zirconium phosphate in a zirconium phosphate sorbent module can begin in
step 101. During use in dialysis potassium, calcium, magnesium, and ammonium ions are adsorbed by the zirconium phosphate. Instep 102, the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy. The spent dialysate can have proteinaceous and other compounds that interact with the disinfectant used in subsequent steps. Rinsing the zirconium phosphate sorbent module with water removes the proteinaceous compounds. Any volume of water sufficient to remove the spent dialysate can be flowed through the zirconium phosphate sorbent module instep 102, including between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L. In a preferred embodiment, about 1.0 L of water is flowed through the zirconium phosphate sorbent module in rinsingstep 102. The rinse water can be flowed through the zirconium phosphate sorbent module at any temperature. In certain embodiments, the rinse water can be heated to aid in removal of spent dialysate or for pre-heating the zirconium phosphate sorbent module. Pre-heating the zirconium phosphate sorbent module can increase efficiency where the zirconium phosphate sorbent module may have been stored at low temperatures, such as 10 °C or less. The rinse water can be heated to any temperature between 20 and 100 °C. - After rinsing the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be filled with a disinfectant solution in
step 103. An aqueous peracetic acid solution can be the disinfectant solution. The peracetic acid solution can have any concentration of peracetic acid sufficient to disinfect the zirconium phosphate sorbent module, including between 0.1 and 5 wt%. In a preferred embodiment, the peracetic acid solution is 1 wt% in water. The volume of peracetic acid flowed into the zirconium phosphate sorbent module can be enough to fill the zirconium phosphate sorbent module, and can be between 100% to 200% or more of the void volume of the zirconium phosphate sorbent module. In a preferred embodiment, a volume of peracetic acid solution flowed into the zirconium phosphate sorbent module is 150% of the module void volume. With a 1.2 L zirconium phosphate sorbent module, 1.8 L of peracetic acid solution can be flowed into the module instep 103. - The peracetic acid solutions can be mixtures of peracetic acid, acetic acid and hydrogen peroxide. Typically, peracetic acid is the result of mixing acetic acid and hydrogen peroxide together, resulting in the generation of peracetic acid in equilibrium with the acetic acid and hydrogen peroxide. There are several varieties of peracetic acid solution available, which vary in the concentration of peracetic acid, acetic acid, and hydrogen peroxide. In addition to peracetic acid, the disinfectant solution can be a combined peracetic acid and acetic acid solution, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The combined disinfectant and acid solution can contain between 0.1 and 3 wt% peracetic acid and 0.1 to 15 wt% acetic acid. Alternatively, hydrogen peroxide can be added to the peracetic acid, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The addition of hydrogen peroxide can drive the equilibrium of peracetic acid, hydrogen peroxide, and acetic acid towards generation of peracetic acid as the initial peracetic acid is consumed. Further, both peracetic acid and hydrogen peroxide can be used as disinfectants alone. Both peracetic acid and hydrogen peroxide operate by oxidation, with each having an oxidation potential of 1.8 electron volts. Adding hydrogen peroxide to the peracetic acid solution can increase the total oxidation potential of the mixture, resulting in a more potent disinfectant. Chemical formulations including mixtures of peracetic acid and hydrogen peroxide are known. The mixtures can be clear, colorless liquids that are miscible with water. The mixtures can be oxidizing agents and disinfectants with a pungent odor, having peracetic acid, acetic acid, and hydrogen peroxide in equilibrium. Thermal decomposition of the mixtures occurs at temperatures above 60 °C. Known compositions of peracetic acid and hydrogen peroxide solutions are available from Evonik, a German corporation. Examples of peracetic acid and hydrogen peroxide solutions include PERACLEAN® 5 having 5% peracetic acid and 26% hydrogen peroxide, PERACLEAN® 10 having 10% peracetic acid and 20% hydrogen peroxide, PERACLEAN® 15 having 15% peracetic acid and 21% hydrogen peroxide, PERACLEAN® 35 having 35% peracetic acid and 7% hydrogen peroxide, and PERACLEAN® 40 having 39% peracetic acid and 4% hydrogen peroxide. As the concentration of peracetic acid in the mixture is decreased, additional hydrogen peroxide can be added to increase effectiveness of the mixture. The formulations, or any other source of peracetic acid and hydrogen peroxide can be diluted to obtain a solution with desired concentrations of peracetic acid and hydrogen peroxide.
- In
step 104, the disinfectant solution can be held in the zirconium phosphate sorbent module for a sufficient length of time to ensure complete disinfection of the zirconium phosphate sorbent module. The hold time can be any length of time, including between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes. The length of the hold time can depend on the temperature of the zirconium phosphate sorbent module, and in a preferred embodiment the hold time can be 15 minutes at 22 °C. Alternatively, the disinfectant solution can be heated in steps 103-104 to a temperature higher than 22 °C, which increases the efficiency of disinfection. The disinfectant can be heated to any temperature, including between 22 °C and 100 °C, between 22 °C and 50 °C, between 22 °C and 35 C, between 30 °C and 50 °C, between 35 °C and 65 °C, between 50 °C and 75 °C, or between 60 °C and 100 °C. Duringstep 104, a low flow rate of fluid through the zirconium phosphate sorbent module can be used to prevent pressure build up in the cartridge resulting from the degradation of peracetic acid. The low flow rate can vary from 1 to 20 ml/min. the low flow rate can have an on/off flow profile by intermittently switching the flow rate on and off while holding the disinfectant solution. The flow rate during the disinfectant hold can be set as 55ml/ min for 15 seconds and 0 ml/min for 45 seconds. In a preferred embodiment, the hold flow rate is 15 cycles of 55 ml/min for 15 seconds and 0-ml/min for 45 seconds. - In
step 105, the zirconium phosphate module can be rinsed with water, allowing a buffer of water to be present between the peracetic acid solution and the subsequent brine solution. Step 105 is optional, and the method can proceed without rinsing between theperacetic acid step 104 and thebrine step 106. When rinsing with water betweensteps step 105 is omitted. However, the zirconium phosphate module can be rinsed if material degradation to the cartridge housing or other components is detected. Material degradation may be an issue if the disinfectant used is a heated mixture of peracetic acid and acetic acid, or a mixture of peracetic acid and brine at temperatures around 80 °C. - In step 106 a brine solution can be flowed through the zirconium phosphate sorbent module to recharge the zirconium phosphate. The brine solution can include an aqueous solution of sodium chloride, and acid, and the sodium salt of the acid. The brine solution provides additional disinfection of the zirconium phosphate; recovers the capacity of the zirconium phosphate by removing ammonium, potassium, calcium, and magnesium ions in exchange for sodium and hydrogen ions; and leaves the zirconium phosphate at the desired pH, or in the proper/desired sodium to hydrogen ion ratio for dialysis. Although
FIG. 1 illustrates flowing the brine solution through the zirconium phosphate sorbent module instep 106 after flowing the disinfectant solution through the zirconium phosphate sorbent module instep 104, the order can be reversed, with the brine solution flowed through the zirconium phosphate module first, followed by the disinfectant solution. Flowing the disinfectant solution through the zirconium phosphate sorbent module after the brine solution can reduce the risk of the brine solution contaminating the cartridge. Further, the disinfectant solution can be kept in the zirconium phosphate sorbent module during storage, preventing microbial growth in the zirconium phosphate sorbent module during storage. - Any acid, sodium salt of an acid, and sodium salt can be used in the brine solution. In a preferred embodiment, the brine solution includes sodium chloride, acetic acid, and sodium acetate. However, the brine solution can be a glycolic/glycolate solution, a citric acid/citrate solution, a propionate/propionic acid solution, monobasic phosphate, or any combination thereof. The relative ratios of the acid and sodium salt of the acid in the brine solution can be varied depending on the desired zirconium phosphate pH. With a sodium acetate/acetic acid brine solution, the concentration of sodium chloride can vary between 0 and 5.0 M, the concentration of acetic acid can vary between 0.1 and 2.0 M, and the concentration of sodium acetate can vary between 0.1 and 2 M, where the upper concentration limits are only limited by solubility. The sodium chloride can be omitted in certain embodiments, and the zirconium phosphate sorbent module can be recharged with an acid and the sodium salt of the acid. The sodium salt of the acid can provide sodium ions and the acid can provide the hydrogen ions for recharging. The upper limit of the sodium salt and acid concentration is based on the solubility of the sodium salt and acid, and can depend on the type of sodium salt used and the acid concentration used. In a preferred embodiment, the brine solution contains about 4.854 M sodium chloride, 0.350 M sodium acetate, and 0.350 M acetic acid. Table 1 provides non-limiting examples of brine solutions and the resulting initial therapy zirconium phosphate effluent pH. In each case, the solution was heated to 80°C prior to use. As shown in Table 1, a higher ratio of sodium acetate to acetic acid results in a higher solution pH, and therefore a higher initial therapy zirconium phosphate effluent pH. The relative amounts of acid, base, and sodium salt can be set to generate a brine solution resulting in a desired initial effluent pH.
Table 1 Solution Total Na (M) NaCl (M) NaAce (M) HAce (M) pH Initial Effluent PH 1 4.00 4.00 0.00 0.20 2.75 4.40 2 4.00 3.98 0.02 0.20 3.74 5.42 3 4.00 3.88 0.12 0.40 4.23 5.99 4 4.00 3.60 0.40 0.40 4.75 6.58 - Each of the solutions in Table 1 are combinations of sodium chloride, sodium acetate, and acetic acid. One of skill in the art will understand that other combinations can be used in place of sodium acetate and acetic acid, including sodium diacetate. The sodium diacetate can be mixed with sodium acetate or acetic acid to result in a brine solution having a desired pH. Sodium diacetate and sodium acetate are solids, which may be easier to ship and store. The sodium diacetate and/or sodium acetate can be shipped and stored as a dry powder, eliminating the need to ship and handle acetic acid.
- During
step 106, the brine solution can optionally be heated. Heating the brine solution increases the efficiency of the recharging process. The brine solution can be heated to any temperature between 22 and 100°C, including between 22 and 40°C, between 22 and 60°C, between 35 and 50°C, between 45 and 70°C, between 55 and 85°C, between 60 and 90°C, between 75 and 85°C, or between 70 and 100°C. In a preferred embodiment, the brine solution is heated to about 80°C duringstep 106. The brine solution can be used at lower temperatures with a decrease in efficiency. - The volume of brine solution to recharge the zirconium phosphate depends on the cations bound to the zirconium phosphate during therapy, and the size of the zirconium phosphate sorbent module, the temperature of the brine solution, and the concentrations of sodium chloride, acid, and sodium salt of the acid used in the brine solution. In a preferred embodiment, the volume of brine is 6.2L for a zirconium phosphate sorbent module containing 2.69kg of ZP with a capacity of 1 mEq cation per gram of ZP.
- After flowing the brine solution through the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be rinsed in
step 107 by flowing water through the zirconium phosphate sorbent module. The rinsing is necessary to remove the brine solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session. The rinse water volume can vary from 100% to 500% of the cartridge void volume. In a preferred embodiment, the volume of rinse water is about 333% of the cartridge void volume, or 4L for a zirconium phosphate sorbent module with a 1.2L void volume. About 99% of the brine solution can be removed from the zirconium phosphate sorbent module duringstep 107, which leaves the zirconium phosphate sorbent module with an average concentration remaining of 52mM total sodium, which is appropriate for storage and use during the next therapy session. The rinsingstep 107 can occur during recharging of the zirconium phosphate sorbent module, or the zirconium phosphate sorbent module can be rinsed in the dialysis system just prior to use. Rinsing the zirconium phosphate sorbent module just prior to use allows the disinfectant solution, if the disinfectant step is performed after the brine step, to remain in the zirconium phosphate sorbent module during storage, reducing microbial growth. The method can end instep 108, with a zirconium phosphate sorbent module in condition for reuse in dialysis. Alternatively, the zirconium phosphate module can be fully or partially drained after recharging and conditioning for storage, which decreases the weight and exposure to water during storage. - The direction of flow of brine through the zirconium phosphate sorbent module during
step 106 can be in a direction opposite to a flow direction during therapy. During therapy, spent dialysate enters the bottom of the module, flows upwards against gravity, and exits the top of the cartridge. During recharging the brine can enter the zirconium phosphate sorbent module at the top and exit through the bottom, flowing with gravity. Alternatively, the spent dialysate flow direction during therapy can be downward, and the brine can flow upwardly through the zirconium phosphate sorbent module during recharging. The rinse and disinfection flow direction during steps 102-105 and 107 can be either the same or opposite to the flow direction during therapy. Alternatively, the direction of flow of brine during recharging can be the same as the flow direction during therapy, however, flowing brine through the zirconium phosphate module in the same direction as flow during therapy may require additional brine volume for recharging. In a preferred embodiment, the rinse and disinfection flow direction is the same direction as the brine flow direction. -
FIG. 2 illustrates an alternative embodiment of the disinfection, recharging, and conditioning of zirconium phosphate. The method can start instep 201. Instep 202, the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy. In step 203 a mixture of disinfectant solution and brine can be flowed through the zirconium phosphate sorbent module. The disinfectant solution can be added to the brine, and the process for recharging, disinfecting, and conditioning the zirconium phosphate sorbent module can be similar to the process illustrated inFIG. 1 , allowing disinfection, capacity recovery, and conditioning in one step. The mixture of disinfectant solution and brine disinfects and recharges the zirconium phosphate in a single step, as opposed to separate steps as illustrated inFIG. 1 . The concentrations of peracetic acid, sodium chloride, sodium acetate, and acetic acid in the mixture can be the same as the individual solutions shown inFIG. 1 . The mixture of brine and peracetic acid may help stabilize the peracetic acid in the disinfectant solution because the presence of the acetate buffer keeps the peracetic acid/acetic acid equilibrium shifted to the peracetic acid side. Duringstep 203, the mixture of peracetic acid and brine can be held in the zirconium phosphate sorbent module for any length of time sufficient to ensure complete disinfection or alternatively, the mixture of peracetic acid and brine can be continuously flowed through the zirconium phosphate sorbent module. In a preferred embodiment, the mixture of peracetic acid and brine is heated to about 80°C instep 203, however the solutions may alternatively be at a lower, unheated temperature, such as room temperature. The mixture of peracetic acid and brine can be heated to any temperature between 22 and 100°C, including between 22 and 40°C, between 22 and 60°C, between 35 and 50°C, between 45 and 70°C, between 55 and 85°C, between 60 and 90°C, between 75 and 85°C, or between 80 and 100°C. Alternatively, the mixture of peracetic acid and brine can be kept at room temperature for a set period of time to ensure complete disinfection, and then heated for a set period of time to increase the efficiency of the recharging process. The mixture of peracetic acid and brine solution can be maintained at room temperature for 5-30 minutes, and then subsequently heated. In a preferred embodiment, about 6.2 L of a solution of 1 wt% peracetic acid and the brine solutions described can be flowed through the zirconium phosphate sorbent module at about 80 °C. Instep 204, the zirconium phosphate sorbent module can be rinsed by flowing water through the zirconium phosphate sorbent module to remove the brine and peracetic acid solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session. The method can end instep 205 with a zirconium phosphate sorbent module in condition for reuse in dialysis. -
FIG. 3 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconiumphosphate sorbent module 302. A zirconiumphosphate sorbent module 302 can connect to the zirconium phosphaterecharging flow path 301 through zirconium phosphatesorbent module inlet 303 and zirconium phosphatesorbent module outlet 304. A zirconiumphosphate effluent line 311 can be fluidly connected to the zirconium phosphatesorbent module outlet 304 for removal of solutions after the solutions pass through the zirconiumphosphate sorbent module 302.Pump 307 provides a driving force for flowing fluids through the zirconium phosphaterecharging flow path 301. Abrine source 305, containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid is fluidly connected to the zirconium phosphaterecharging flow path 301.Disinfectant source 306 can contain a disinfectant solution, such as peracetic acid.Water source 310 is also fluidly connected to the zirconium phosphaterecharging flow path 301. Thewater source 310 can contain any water as defined herein, including deionized water. The water can be obtained from a tap such as a faucet or from any other readily available source in a home setting. Water obtained from a tap is not limited to any specific country requirements and contemplates various water specifications insofar as various countries may have different requirements. In general, the water should not be contamined by infectious agents, toxic chemicals, or radiological hazards. The water can comport with WHO requirements for potable or drinking water. However, the invention contemplating water from many sources having various purity and quality levels and requirements, shall not be limited in such respects.Valve 308 controls the movement of fluid through the zirconium phosphaterecharging flow path 301 and zirconiumphosphate sorbent module 302. Astatic mixer 309 can optionally be included to ensure complete mixing of solutions prior to entering the zirconiumphosphate sorbent module 302. For example, when a mixture of brine and peracetic acid is used for single step disinfecting and recharging, thestatic mixer 309 ensures that the peracetic acid and brine are mixed to generate a dilute mixture of brine and peracetic acid for simultaneous recharging and disinfection. One of skill in the art will understand that different pump and valve arrangements can be used with the system illustrated inFIG. 3 . Thebrine source 305,disinfectant source 306, andwater source 310 can be connected to the zirconium phosphaterecharging flow path 301 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphaterecharging flow path 301. - The zirconium phosphate
recharging flow path 301 can flow solutions through the zirconiumphosphate sorbent module 302 in a sequential order or simultaneously. As illustrated inFIG. 1 , the zirconium phosphaterecharging flow path 301 can flow water, disinfectant, brine, and water again through the zirconiumphosphate sorbent module 302 sequentially. The zirconium phosphaterecharging flow path 301 can flow water through the zirconiumphosphate sorbent module 302, followed by simultaneously flowing peracetic acid and brine through the zirconiumphosphate sorbent module 302 as illustrated inFIG. 2 . - The solutions in the
brine source 305 anddisinfectant source 306 can be any concentration, including the concentrations shown in FIG.'s 1-2. The solutions inbrine source 305 and/ordisinfectant source 306 can be concentrated solutions. The brine solution can have sodium chloride, acid, and sodium salt of the acid at concentrations higher than that to be used in recharging the zirconiumphosphate sorbent module 302. The brine solution and water can be simultaneously flowed tostatic mixer 309 to dilute the concentrated brine solution in the recharging steps generating a dilute brine solution usable for recharging the zirconium phosphate. Similarly, a concentrated disinfectant solution and water can be simultaneously flowed tostatic mixer 309 to dilute the disinfectant solution during the disinfecting steps, generating a dilute disinfectant solution for disinfecting the zirconium phosphate. A heater and/or heat exchanger (not shown) can be included for heating the brine solution, the disinfectant solution, and/or the rinse water prior to flowing the solutions through the zirconiumphosphate sorbent module 302. -
FIG. 4 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconiumphosphate sorbent module 402 with a combined brine and disinfectant fluid, as illustrated inFIG. 2 . A zirconiumphosphate sorbent module 402 can connect to the zirconium phosphaterecharging flow path 401 through zirconium phosphatesorbent module inlet 403 and zirconium phosphatesorbent module outlet 404. A zirconiumphosphate effluent line 410 can be fluidly connected to the zirconium phosphatesorbent module outlet 404 for removal of solutions after the solutions pass through the zirconiumphosphate sorbent module 402.Pump 407 provides a driving force for flowing fluids through the zirconium phosphaterecharging flow path 401. A combined disinfectant solution andbrine solution source 405, containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid, and a disinfectant such as peracetic acid, can be fluidly connected to the zirconium phosphaterecharging flow path 401.Water source 406 is also fluidly connected to the zirconium phosphaterecharging flow path 401.Valve 408 controls the movement of fluid through the zirconium phosphaterecharging flow path 401 and zirconiumphosphate sorbent module 402. Astatic mixer 409 can optionally be included to ensure complete mixing of solutions prior to entering the zirconiumphosphate sorbent module 402 and can generate a dilute solution from the combined disinfectant solution andbrine solution source 405 when a concentrated solution is used. One of skill in the art will understand that different pump and valve arrangements can be used with the system illustrated inFIG. 4 . For example, the combined disinfectant solution andbrine solution source 405 andwater source 406 can be connected to the zirconium phosphaterecharging flow path 401 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphaterecharging flow path 401. A heater and/or heat exchanger (not shown) can be included for heating the combined disinfectant solution and brine solution and/or the rinse water prior to flowing the solutions through the zirconiumphosphate sorbent module 402. - One skilled in the art will understand that various combinations and/or modifications and variations can be made in the described systems and methods depending upon the specific needs for operation. Moreover features illustrated or described as being part of an aspect of the invention may be used in the aspect of the invention, either alone or in combination.
- The invention may be described by reference to the following numbered paragraphs:-
- 1. A method of recharging zirconium phosphate in a zirconium phosphate sorbent module, comprising the steps of:
- flowing a disinfectant solution through the zirconium phosphate sorbent module; and
- flowing a brine solution through the zirconium phosphate sorbent module.
- 2. The method of paragraph 1, further comprising the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
- 3. The method of paragraph 1, wherein the disinfectant solution is a peracetic acid solution and the brine solution contains acetic acid, sodium acetate, and sodium chloride.
- 4. The method of paragraph 3, wherein the brine solution contains between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- 5. The method of paragraph 3, wherein the disinfectant solution contains between 0.1 and 3.0 wt% peracetic acid.
- 6. The method of paragraph 3, wherein the disinfectant solution contains between 0.1 and 3.0 wt% peracetic acid and between 0.1 to 15 wt% acetic acid.
- 7. The method of paragraph 3, wherein the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module comprises flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- 8. The method of paragraph 7, wherein the mixture of the disinfectant solution and the brine solution is maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.
- 9. The method of paragraph 7, wherein the mixture of the disinfectant solution and the brine solution is maintained at room temperature for a set period of time, and then heated for a set period of time.
- 10. The method of paragraph 7, wherein the mixture of the disinfectant solution and the brine solution comprises between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- 11. The method of paragraph 1, wherein the step of flowing the disinfectant solution through the zirconium phosphate sorbent module comprises flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.
- 12. The method of paragraph 1, wherein the step of flowing a brine solution through the zirconium phosphate sorbent module comprises flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
- 13. The method of paragraph 3, wherein the brine solution is flowed through the zirconium phosphate sorbent module after the peracetic acid solution is flowed through the zirconium phosphate sorbent module.
- 14. The method of paragraph 3, wherein the peracetic acid solution is flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.
- 15. The method of paragraph 1, further comprising the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module.
- 16. The method of paragraph 15, wherein the brine solution is heated to a temperature of between 70°C and 100 °C.
- 17. The method of paragraph 7, further comprising the step of flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- 18. The method of paragraph 7, wherein the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module comprises flowing the mixture from a combined disinfectant solution and brine solution source.
- 19. The method of paragraph 1, further comprising the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.
- 20. The method of paragraph 19, wherein the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module comprises flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.
- 21. The method of paragraph 1, further comprising the step of holding the disinfectant solution in the zirconium phosphate sorbent module.
- 22. The method of paragraph 21, wherein the disinfectant solution is held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
- 23. The method of paragraph 21, further comprising the step of flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.
- 24. The method of paragraph 21, further comprising the step of intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.
- 25. The method of paragraph 21, further comprising the step of rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.
- 26. The method of paragraph 2, wherein the brine solution, the water, and the disinfectant solution are flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
- 27. A zirconium phosphate recharging flow path, comprising:
- i. a water source and a combined disinfectant solution and brine solution source;
- ii. a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module;
- iii. at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; and
- iv. a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet.
- 28. The zirconium phosphate recharging flow path of paragraph 27, wherein the combined disinfectant solution and brine solution source comprises between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- 29. The zirconium phosphate recharging flow path of paragraph 27, further comprising at least a second pump.
- 30. The zirconium phosphate recharging flow path of paragraph 29, further comprising a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.
Claims (15)
- A method of recharging zirconium phosphate in a zirconium phosphate sorbent
module, comprising the steps of:flowing a disinfectant solution through the zirconium phosphate sorbent module; andflowing a brine solution through the zirconium phosphate sorbent module. - The method of claim 1, further comprising the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
- The method of claim 1, wherein the disinfectant solution is a peracetic acid solution and the brine solution contains acetic acid, sodium acetate, and sodium chloride; preferably wherein the brine solution contains between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid; and/or wherein the disinfectant solution contains between 0.1 and 3.0 wt% peracetic acid; most preferably wherein the disinfectant solution contains between 0.1 and 3.0 wt% peracetic acid and between 0.1 to 15 wt% acetic acid.
- The method of claim 3, wherein the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module comprises flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
- The method of claim 4, wherein the mixture of the disinfectant solution and the brine solution is maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.
- The method of claim 4, wherein the mixture of the disinfectant solution and the brine solution is maintained at room temperature for a set period of time, and then heated for a set period of time.
- The method of any of claims 4 to 6, wherein the mixture of the disinfectant solution and the brine solution comprises between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
- The method of claim 1, wherein the step of flowing the disinfectant solution through the zirconium phosphate sorbent module comprises flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module; and/or wherein the step of flowing a brine solution through the zirconium phosphate sorbent module comprises flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
- The method of claim 3, wherein the brine solution is flowed through the zirconium phosphate sorbent module after the peracetic acid solution is flowed through the zirconium phosphate sorbent module; or wherein the peracetic acid solution is flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.
- The method of claim 1, further comprising the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module; preferably, wherein the brine solution is heated to a temperature of between 70°C and 100 °C.
- The method of claim 4, further comprising the step of flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module; or wherein the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module comprises flowing the mixture from a combined disinfectant solution and brine solution source.
- The method of claim 1, further comprising the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module; preferably, wherein the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module comprises flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.
- The method of claim 1, further comprising the step of holding the disinfectant solution in the zirconium phosphate sorbent module; preferably, wherein the disinfectant solution is held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes; and/or, further comprising the step of flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module; and/or, further comprising the step of intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module; and/or further comprising the step of rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.
- The method of any of claims 2 to 13, wherein the brine solution, the water, and the disinfectant solution are flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
- A zirconium phosphate recharging flow path, comprising:i. a water source and a combined disinfectant solution and brine solution source;ii. a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module;iii. at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; andiv. a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet;preferably, wherein the combined disinfectant solution and brine solution source comprises between 0.1 and 3.0 wt% peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid; and/or further comprising at least a second pump; and/or further comprising a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762519933P | 2017-06-15 | 2017-06-15 | |
US15/958,337 US10960381B2 (en) | 2017-06-15 | 2018-04-20 | Zirconium phosphate disinfection recharging and conditioning |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3415182A1 true EP3415182A1 (en) | 2018-12-19 |
EP3415182B1 EP3415182B1 (en) | 2022-05-04 |
Family
ID=62636066
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18177673.3A Active EP3415182B1 (en) | 2017-06-15 | 2018-06-14 | Zirconium phosphate disinfection recharging and conditioning |
Country Status (3)
Country | Link |
---|---|
US (2) | US10960381B2 (en) |
EP (1) | EP3415182B1 (en) |
CN (1) | CN109126682A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020113066A1 (en) * | 2018-11-28 | 2020-06-04 | Baxter International Inc. | Systems and methods for onsite sorbent material reuse |
WO2020113069A1 (en) * | 2018-11-28 | 2020-06-04 | Baxter International Inc. | Systems and methods for batch sorbent material reuse |
US11925916B2 (en) | 2018-11-28 | 2024-03-12 | Baxter International Inc. | Method and composition for removing uremic toxins |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150108069A1 (en) * | 2013-10-23 | 2015-04-23 | Fresenius Medical Care Holdings, Inc. | Process For Regeneration Of Spent Zirconium Phosphate For Reuse in Sorbent Treatments |
US20150367055A1 (en) * | 2014-06-24 | 2015-12-24 | Medtronic, Inc. | Method of zirconium phosphate recharging |
US20160236188A1 (en) * | 2013-11-26 | 2016-08-18 | Medtronic, Inc. | MANAGEMENT OF RECHARGER EFFLUENT pH |
US20160243541A1 (en) * | 2013-11-26 | 2016-08-25 | Medtronic, Inc. | Zirconium phosphate and zirconium oxide recharging flow paths |
Family Cites Families (407)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1617288A (en) | 1925-03-16 | 1927-02-08 | Zeolite Engineering Co | Method of and apparatus for reconditioning zeolite water softeners |
US2703313A (en) | 1950-01-09 | 1955-03-01 | Aerojet General Co | Cation exchange apparatus |
GB1189458A (en) | 1967-09-27 | 1970-04-29 | Nat Res Dev | Improvements in or relating to dialysers |
US3669878A (en) | 1968-12-02 | 1972-06-13 | Health Education And Welfare U | Treatment of dialysate solution for removal of urea |
FR2036413A5 (en) | 1969-03-13 | 1970-12-24 | Thomson Csf | |
US3669880A (en) | 1969-06-30 | 1972-06-13 | Cci Aerospace Corp | Recirculation dialysate system for use with an artificial kidney machine |
US3776819A (en) | 1969-12-22 | 1973-12-04 | Monsanto Co | Urea determination and electrode therefor |
US3617558A (en) | 1970-11-02 | 1971-11-02 | Illinois Water Treatment Co | Layered ion exchange process |
DE2239254C2 (en) | 1970-12-30 | 1983-08-04 | Organon Teknika Corp., Oklahoma City, Okla. | "Column for regenerating a circulating dialysate solution and using this column". |
US3850835A (en) | 1971-11-08 | 1974-11-26 | Cci Life Systems Inc | Method of making granular zirconium hydrous oxide ion exchangers, such as zirconium phosphate and hydrous zirconium oxide, particularly for column use |
US3884808A (en) | 1973-06-20 | 1975-05-20 | Res Dev Systems Inc | Wearable, self-regenerating dialysis appliance |
SE373752B (en) | 1973-07-05 | 1975-02-17 | V H Hyden | |
US4192748A (en) | 1973-07-05 | 1980-03-11 | Hyden Viktor H | Dialysis apparatus with selective chemical activity |
US3840835A (en) | 1973-09-04 | 1974-10-08 | Chase Shawmut Co | Electric current-limiting low voltage fuse |
US3902490A (en) | 1974-03-27 | 1975-09-02 | Univ Utah | Portable artificial kidney system |
JPS5155193A (en) | 1974-11-07 | 1976-05-14 | Kanebo Ltd | |
US4073725A (en) | 1975-05-09 | 1978-02-14 | Hitachi, Ltd. | Method and apparatus for liquid chromatography under elevated pressure |
JPS51131393A (en) | 1975-05-09 | 1976-11-15 | Hitachi Ltd | High pressure choromatography and its device |
US4060485A (en) | 1975-06-09 | 1977-11-29 | I T L Technology, Inc. | Dialysis apparatus |
US4142845A (en) | 1976-02-20 | 1979-03-06 | Lepp William A | Dialysis pump system having over-center cam tracks to lock rollers against tubing |
US4094775A (en) | 1977-02-28 | 1978-06-13 | California Institute Of Technology | Dialysis system |
US4581141A (en) | 1978-02-27 | 1986-04-08 | Purdue Research Foundation | Dialysis material and method for removing uremic substances |
IT1174707B (en) | 1978-05-03 | 1987-07-01 | Bonomini Vittorio | PORTABLE ARTIFICIAL KIDNEY FOR DIALYSIS |
US4209392A (en) | 1978-05-15 | 1980-06-24 | Wallace Richard A | Portable hepatic-assist method and apparatus for same |
US4206054A (en) | 1978-10-27 | 1980-06-03 | Leon Moore | Pyramidic aquarium filter-aerator |
US4376707A (en) | 1979-05-21 | 1983-03-15 | Gambro Dialysatoren G.M.B.H. & Co. K.G. | Process for the removal of urea from blood wash fluids and blood |
US4556063A (en) | 1980-10-07 | 1985-12-03 | Medtronic, Inc. | Telemetry system for a medical device |
US4374382A (en) | 1981-01-16 | 1983-02-15 | Medtronic, Inc. | Marker channel telemetry system for a medical device |
DE3110128A1 (en) | 1981-03-16 | 1982-09-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Process and apparatus for the detoxication and regeneration of blood, blood constituents and solutions resulting from the purification of blood, as well as kit for carrying out the process |
US4381999A (en) | 1981-04-28 | 1983-05-03 | Cobe Laboratories, Inc. | Automatic ultrafiltration control system |
US4371385A (en) | 1981-04-28 | 1983-02-01 | Cobe Laboratories, Inc. | Deaerating liquid |
US4750494A (en) | 1981-05-12 | 1988-06-14 | Medtronic, Inc. | Automatic implantable fibrillation preventer |
US4612122A (en) | 1981-06-29 | 1986-09-16 | Clara Ambrus | Removing heavy metal ions from blood |
US4460555A (en) | 1983-08-25 | 1984-07-17 | Organon Teknika Corporation | Ammonia scavenger |
US4650587A (en) | 1982-09-09 | 1987-03-17 | Akzona Incorporated | Ammonia scavenger |
US4678408A (en) | 1984-01-06 | 1987-07-07 | Pacesetter Infusion, Ltd. | Solenoid drive apparatus for an external infusion pump |
US4562751A (en) | 1984-01-06 | 1986-01-07 | Nason Clyde K | Solenoid drive apparatus for an external infusion pump |
US4685903A (en) | 1984-01-06 | 1987-08-11 | Pacesetter Infusion, Ltd. | External infusion pump apparatus |
US4765907A (en) | 1984-03-28 | 1988-08-23 | Research Development Systems, Inc. | Wearable, continuously internally operable and externally regenerable dialysis device |
US4661246A (en) | 1984-10-01 | 1987-04-28 | Ash Medical Systems, Inc. | Dialysis instrument with dialysate side pump for moving body fluids |
FR2574664B1 (en) | 1984-12-14 | 1987-03-06 | Issautier Gerald | HEMODIALYSIS DEVICE FOR AUTOMATICALLY CONTROLLING WEIGHT LOSS |
JPS61164562A (en) | 1985-01-16 | 1986-07-25 | 鐘淵化学工業株式会社 | Apparatus and method for treatment of body fluid component |
IT1191613B (en) | 1985-05-15 | 1988-03-23 | Eniricerche Spa | ZIRCONIUM PHOSPHATE AND ITS PREPARATION METHOD |
US4687582A (en) | 1985-12-23 | 1987-08-18 | Dixon Walter O | Method and apparatus for operating and regenerating ion exchangers |
DE3634763A1 (en) | 1986-10-11 | 1988-04-28 | Josef Magasi | DEVICE AND METHOD FOR CLEANING BLOOD |
EP0266795B2 (en) | 1986-11-07 | 1996-03-27 | Asahi Kasei Kogyo Kabushiki Kaisha | Improved regenerated cellulose membrane and process for preparation thereof |
US4828693A (en) | 1987-09-22 | 1989-05-09 | Baxter Travenol Laboratories, Inc. | Water pressure regulator for hemodialysis apparatus |
GB8722854D0 (en) | 1987-09-29 | 1987-11-04 | Hardy S M | Implantable artificial kidney |
CA1327838C (en) | 1988-06-13 | 1994-03-15 | Fred Zacouto | Implantable device to prevent blood clotting disorders |
DE3912405C1 (en) | 1989-04-15 | 1990-10-31 | B. Braun Melsungen Ag, 3508 Melsungen, De | |
US5032615A (en) | 1989-10-31 | 1991-07-16 | The Regents Of The University Of California | Continuous hemodialysis using citrate |
US5477864A (en) | 1989-12-21 | 1995-12-26 | Smith & Nephew Richards, Inc. | Cardiovascular guidewire of enhanced biocompatibility |
US5127404A (en) | 1990-01-22 | 1992-07-07 | Medtronic, Inc. | Telemetry format for implanted medical device |
US5080653A (en) | 1990-04-16 | 1992-01-14 | Pacesetter Infusion, Ltd. | Infusion pump with dual position syringe locator |
US5097122A (en) | 1990-04-16 | 1992-03-17 | Pacesetter Infusion, Ltd. | Medication infusion system having optical motion sensor to detect drive mechanism malfunction |
JPH0490963A (en) | 1990-08-06 | 1992-03-24 | Toshiba Corp | Steering truck |
JP2981573B2 (en) | 1990-12-12 | 1999-11-22 | 富田製薬株式会社 | Phosphate ion adsorbent |
US5230702A (en) | 1991-01-16 | 1993-07-27 | Paradigm Biotechnologies Partnership | Hemodialysis method |
US5486286A (en) | 1991-04-19 | 1996-01-23 | Althin Medical, Inc. | Apparatus for performing a self-test of kidney dialysis membrane |
FR2680976B1 (en) | 1991-09-10 | 1998-12-31 | Hospal Ind | ARTIFICIAL KIDNEY PROVIDED WITH BLOOD CHARACTERISTIC MEANS OF DETERMINATION AND CORRESPONDING DETERMINATION METHOD. |
JPH0599464A (en) | 1991-10-08 | 1993-04-20 | Nec Corp | Air shower device |
US5192132A (en) | 1991-12-12 | 1993-03-09 | Mobil Oil Corporation | Temperature monitoring of a fixed-bed catalytic reactor |
FR2687307B1 (en) | 1992-02-14 | 1999-06-04 | Lascombes Jean Jacques | DEVICE FOR THE PREPARATION OF A SOLUTION FOR MEDICAL USE. |
FR2693110B1 (en) | 1992-07-06 | 1994-08-19 | Hospal Ind | Method for verifying the operation of sensors located on a dialysis liquid circuit and device using it. |
DE69330804T2 (en) | 1992-10-13 | 2002-07-18 | Baxter International Inc., Deerfield | Hemodialysis monitoring system for dialysis machines |
WO1994009351A1 (en) | 1992-10-13 | 1994-04-28 | Baxter International Inc. | Fluid sampling module |
US5849179A (en) | 1992-10-13 | 1998-12-15 | Baxter International Inc. | Automatic apparatus for obtaining equilibration samples of dialysate |
US5284470A (en) | 1992-11-02 | 1994-02-08 | Beltz Alex D | Wearable, portable, light-weight artificial kidney |
US5441049A (en) | 1992-12-28 | 1995-08-15 | Automata Medical Instrumentation, Inc. | Conductivity meter |
US5445610A (en) | 1993-01-15 | 1995-08-29 | University Of Cincinnati | Portable peritoneal dialysis cycler |
IT1260614B (en) | 1993-03-01 | 1996-04-22 | Sorin Biomedica Spa | PROCEDURE FOR MEASURING THE CONCENTRATION OF A SUBSTANCE IN A FLUID, ITS SYSTEM AND USE |
US5302288A (en) | 1993-03-19 | 1994-04-12 | Zimpro Environmental, Inc. | Treatment of highly colored wastewaters |
DE4321927C2 (en) | 1993-07-01 | 1998-07-09 | Sartorius Gmbh | Filter unit with degassing device |
US5308315A (en) | 1993-07-27 | 1994-05-03 | Raja N. Khuri | Method for determining the adequacy of dialysis |
US5685988A (en) | 1993-09-15 | 1997-11-11 | Malchesky; Paul | Dialysis process and system |
US5507723A (en) | 1994-05-24 | 1996-04-16 | Baxter International, Inc. | Method and system for optimizing dialysis clearance |
WO1996004401A1 (en) | 1994-07-29 | 1996-02-15 | Gambro Ab | Method and device for measuring the concentration of a substance in a solution |
US6572769B2 (en) | 1994-09-26 | 2003-06-03 | Rajan G. Rajan | Water treatment apparatus |
US5591344A (en) | 1995-02-13 | 1997-01-07 | Aksys, Ltd. | Hot water disinfection of dialysis machines, including the extracorporeal circuit thereof |
SE504633C2 (en) | 1995-07-03 | 1997-03-24 | Althin Madical Ab | Device for dialysis machine |
IT1276468B1 (en) | 1995-07-04 | 1997-10-31 | Hospal Dasco Spa | AUTOMATIC DIALYSIS METHOD AND EQUIPMENT |
US5944684A (en) | 1995-08-31 | 1999-08-31 | The Regents Of The University Of California | Wearable peritoneum-based system for continuous renal function replacement and other biomedical applications |
US5938634A (en) | 1995-09-08 | 1999-08-17 | Baxter International Inc. | Peritoneal dialysis system with variable pressure drive |
US6363279B1 (en) | 1996-01-08 | 2002-03-26 | Impulse Dynamics N.V. | Electrical muscle controller |
US5683432A (en) | 1996-01-11 | 1997-11-04 | Medtronic, Inc. | Adaptive, performance-optimizing communication system for communicating with an implanted medical device |
US20090012864A1 (en) | 2007-07-02 | 2009-01-08 | Goldberg Sheldon F | Compensation model for network services |
US5770086A (en) | 1996-01-25 | 1998-06-23 | Eureka| Science Corp. | Methods and apparatus using hydrogels |
JP2000513224A (en) | 1996-06-24 | 2000-10-10 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Automated and sealed recirculating aquaculture filtration system |
JP3206439B2 (en) | 1996-06-28 | 2001-09-10 | 東海興業株式会社 | Molding manufacturing method and apparatus |
US6048732A (en) | 1996-10-16 | 2000-04-11 | Board Of Regents, The University Of Texas System | Receptor and method for citrate determination |
IT1288767B1 (en) | 1996-10-18 | 1998-09-24 | Hospal Dasco Spa | METHOD OF DETERMINING THE VALUE OF THE RECIRCULATION OF A SUSPENSION SUBJECT TO TREATMENT. |
US5858186A (en) | 1996-12-20 | 1999-01-12 | The Regents Of The University Of California | Urea biosensor for hemodialysis monitoring |
US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
US5931801A (en) | 1997-01-21 | 1999-08-03 | Vasca, Inc. | Valve port assembly with interlock |
US6852090B2 (en) | 1997-02-14 | 2005-02-08 | Nxstage Medical, Inc. | Fluid processing systems and methods using extracorporeal fluid flow panels oriented within a cartridge |
SE513034C2 (en) | 1997-06-02 | 2000-06-19 | Gambro Lundia Ab | Calculation of dialysis efficiency, especially by monitoring urea concentration |
EP1927370B1 (en) | 1997-08-13 | 2013-10-02 | Fresenius Medical Care Deutschland GmbH | Method for setting parameters for hemodialysis and blood processing device with a device for setting parameters for hemodialysis |
SE9703600D0 (en) | 1997-10-02 | 1997-10-02 | Pacesetter Ab | Heart stimulator |
US6390969B1 (en) | 1997-10-09 | 2002-05-21 | Orqis Medical Corporation | Implantable heart assist system and method of applying same |
US6088608A (en) | 1997-10-20 | 2000-07-11 | Alfred E. Mann Foundation | Electrochemical sensor and integrity tests therefor |
SE9703958D0 (en) | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for determination of concentration |
US6648845B1 (en) | 1998-01-07 | 2003-11-18 | Fresenius Medical Care North America | Method and apparatus for determining hemodialysis parameters |
SE520638C2 (en) | 1998-01-21 | 2003-08-05 | Gambro Lundia Ab | Safety device for dialysis machine |
SE9800407D0 (en) | 1998-02-12 | 1998-02-12 | Pacesetter Ab | Heart stimulator |
US6197197B1 (en) | 1998-04-23 | 2001-03-06 | Dialysis Systems, Inc. | Method for fluid delivery in a dialysis clinic |
US6058331A (en) | 1998-04-27 | 2000-05-02 | Medtronic, Inc. | Apparatus and method for treating peripheral vascular disease and organ ischemia by electrical stimulation with closed loop feedback control |
US6358422B1 (en) | 1998-05-14 | 2002-03-19 | Amcol International Corporation | Method and apparatus for removing oil from water including monitoring of absorbent saturation |
SE525639C2 (en) | 1998-06-04 | 2005-03-22 | Thore Falkvall | Determination of slag products in dialysis fluid by means of optical sensor |
US6177049B1 (en) | 1998-06-10 | 2001-01-23 | Dsu Medical Corporation | Reversing flow blood processing system |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
US6593747B2 (en) | 1998-10-05 | 2003-07-15 | The University Of Western Ontario | Method and apparatus for monitoring adsorbent activity in situ |
JP4267206B2 (en) | 1998-10-29 | 2009-05-27 | メドトロニック ミニメド インコーポレイテッド | Reservoir connector |
US6248093B1 (en) | 1998-10-29 | 2001-06-19 | Minimed Inc. | Compact pump drive system |
EP1144024B1 (en) | 1998-12-24 | 2007-02-21 | Fresenius Medical Care Deutschland GmbH | Device for determining the volume of distribution of a blood component during an extracorporeal blood treatment |
GB9828696D0 (en) | 1998-12-29 | 1999-02-17 | Houston J G | Blood-flow tubing |
US6254567B1 (en) | 1999-02-26 | 2001-07-03 | Nxstage Medical, Inc. | Flow-through peritoneal dialysis systems and methods with on-line dialysis solution regeneration |
US6274103B1 (en) | 1999-03-26 | 2001-08-14 | Prismedical Corporation | Apparatus and method for preparation of a peritoneal dialysis solution |
US6230059B1 (en) | 1999-03-17 | 2001-05-08 | Medtronic, Inc. | Implantable monitor |
SE9901165D0 (en) | 1999-03-30 | 1999-03-30 | Gambro Lundia Ab | Method, apparatus and components of dialysis systems |
CA2368809C (en) | 1999-04-30 | 2005-10-25 | John J. Bissler | Hemofiltration system |
EP1072282A1 (en) | 1999-07-19 | 2001-01-31 | EndoArt S.A. | Flow control device |
US6491993B1 (en) | 1999-08-12 | 2002-12-10 | Pactiv Corporation | Absorbent pouches |
DE19938691A1 (en) | 1999-08-14 | 2001-02-15 | Volkswagen Ag | Traffic-guided influencing and/or support of motor vehicles involves detecting objects, including relative speed, using distance measurements to detect traffic situations |
US6272377B1 (en) | 1999-10-01 | 2001-08-07 | Cardiac Pacemakers, Inc. | Cardiac rhythm management system with arrhythmia prediction and prevention |
WO2001051117A1 (en) | 2000-01-11 | 2001-07-19 | Blatter Duane D | Vascular occlusal balloons and related vascular access devices and systems |
US6602399B1 (en) | 2000-03-22 | 2003-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften E.V. | Signal recording of a receptor-effector-system by an extracellular planar potential-sensitive electrode |
US20010041869A1 (en) | 2000-03-23 | 2001-11-15 | Causey James D. | Control tabs for infusion devices and methods of using the same |
IL136079A0 (en) | 2000-04-19 | 2001-05-20 | Cheetah Medical Inc C O Pepper | Method and apparatus for monitoring the cardiovascular condition, particularly the degree of arteriosclerosis in individuals |
WO2001085295A2 (en) | 2000-05-05 | 2001-11-15 | Hemocleanse, Inc. | Use of magnetic particles or other particles having relatively high density in a fluid for mixing and/or leak detection |
US6890315B1 (en) | 2000-05-23 | 2005-05-10 | Chf Solutions, Inc. | Method and apparatus for vein fluid removal in heart failure |
US6589229B1 (en) | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
US6585675B1 (en) | 2000-11-02 | 2003-07-01 | Chf Solutions, Inc. | Method and apparatus for blood withdrawal and infusion using a pressure controller |
US7033498B2 (en) | 2000-11-28 | 2006-04-25 | Renal Solutions, Inc. | Cartridges useful in cleaning dialysis solutions |
US6627164B1 (en) | 2000-11-28 | 2003-09-30 | Renal Solutions, Inc. | Sodium zirconium carbonate and zirconium basic carbonate and methods of making the same |
ES2256164T7 (en) | 2000-12-12 | 2010-03-31 | Jurag Separation A/S | A METHOD AND APPARATUS FOR THE ISOLATION OF IONIC SPECIES FROM A LIQUID. |
JP4276834B2 (en) | 2000-12-27 | 2009-06-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Biological information and blood processing apparatus information management system |
US6579460B1 (en) | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
US6773412B2 (en) | 2001-04-13 | 2004-08-10 | Chf Solutions, Inc. | User interface for blood treatment device |
DE50204545D1 (en) | 2001-06-27 | 2006-02-23 | Siemens Ag | RADIO COMMUNICATION SYSTEM AND METHOD OF OPERATION THEREOF |
US7241272B2 (en) | 2001-11-13 | 2007-07-10 | Baxter International Inc. | Method and composition for removing uremic toxins in dialysis processes |
US7309323B2 (en) | 2001-11-16 | 2007-12-18 | National Quality Care, Inc. | Wearable continuous renal replacement therapy device |
US20060241543A1 (en) | 2001-11-16 | 2006-10-26 | National Quality Care, Inc. | Method for installing and servicing a wearable continuous renal replacement therapy device |
US6960179B2 (en) | 2001-11-16 | 2005-11-01 | National Quality Care, Inc | Wearable continuous renal replacement therapy device |
SE525132C2 (en) | 2001-11-23 | 2004-12-07 | Gambro Lundia Ab | Method of operation of dialysis device |
US6878283B2 (en) | 2001-11-28 | 2005-04-12 | Renal Solutions, Inc. | Filter cartridge assemblies and methods for filtering fluids |
US20030114787A1 (en) | 2001-12-13 | 2003-06-19 | Victor Gura | Wearable peritoneal dialysis system |
US20030113931A1 (en) | 2001-12-14 | 2003-06-19 | Li Pan | Ammonia and ammonium sensors |
US6695807B2 (en) | 2002-01-18 | 2004-02-24 | Dsu Medical, Inc. | Blood flow reversing system |
US6878258B2 (en) | 2002-02-11 | 2005-04-12 | Applied Materials, Inc. | Apparatus and method for removing contaminants from semiconductor copper electroplating baths |
US6711439B1 (en) | 2002-02-14 | 2004-03-23 | Pacesetter, Inc. | Evoked response variability as an indicator of autonomic tone and surrogate for patient condition |
JP3820163B2 (en) | 2002-02-22 | 2006-09-13 | 三井化学株式会社 | Urea concentration measuring method and apparatus |
US7076299B2 (en) | 2002-03-28 | 2006-07-11 | Tran Thong | Method and apparatus for preventing heart tachyarrhythmia |
US6878285B2 (en) | 2002-04-17 | 2005-04-12 | Watervisions International, Inc. | Ion-exchange based fluid treatment systems |
US7153286B2 (en) | 2002-05-24 | 2006-12-26 | Baxter International Inc. | Automated dialysis system |
EP1523347B1 (en) | 2002-07-19 | 2011-05-18 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
ATE505223T1 (en) | 2002-07-19 | 2011-04-15 | Baxter Int | SYSTEM FOR PERITONEAL DIALYSIS |
ATE454176T1 (en) | 2002-07-19 | 2010-01-15 | Baxter Int | SYSTEM FOR PERITONEAL DIALYSIS |
ATE298595T1 (en) | 2002-09-05 | 2005-07-15 | Gambro Lundia Ab | CONTROL FOR A BLOOD TREATMENT DEVICE |
US6945640B2 (en) | 2002-09-11 | 2005-09-20 | Inke Pte. Ltd. | Refill station |
US7128727B2 (en) | 2002-09-30 | 2006-10-31 | Flaherty J Christopher | Components and methods for patient infusion device |
US7144384B2 (en) | 2002-09-30 | 2006-12-05 | Insulet Corporation | Dispenser components and methods for patient infusion device |
WO2004039436A1 (en) | 2002-10-30 | 2004-05-13 | Gambro Lundia Ab | A method and an apparatus for determining the efficiency of dialysis |
US20040099593A1 (en) | 2002-11-25 | 2004-05-27 | Potito De Paolis | Concurrent dialysate purification cartridge |
US7060190B2 (en) | 2003-02-27 | 2006-06-13 | King Technology | Dual dispenser |
EP1592494B1 (en) | 2003-01-07 | 2009-06-24 | NxStage Medical, Inc. | Batch filtration system for preparation of sterile replacement fluid for renal therapy |
WO2004066121A2 (en) | 2003-01-15 | 2004-08-05 | Nxstage Medical Inc. | Waste balancing for extracorporeal blood treatment systems |
US7276042B2 (en) | 2003-01-23 | 2007-10-02 | National Quality Care, Inc. | Low hydraulic resistance cartridge |
US6861473B2 (en) | 2003-02-28 | 2005-03-01 | Baxter International Inc. | Macromolecular ketoaldehydes |
US7326576B2 (en) | 2003-04-09 | 2008-02-05 | Prescient Medical, Inc. | Raman spectroscopic monitoring of hemodialysis |
DE10317024A1 (en) | 2003-04-11 | 2004-11-11 | Fresenius Medical Care Deutschland Gmbh | Blood treatment device |
US7330750B2 (en) | 2003-04-25 | 2008-02-12 | Instrumentarium Corp. | Estimation of cardiac death risk |
US7169303B2 (en) | 2003-05-28 | 2007-01-30 | Hemocleanse Technologies, Llc | Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems |
EP1506809A1 (en) | 2003-08-11 | 2005-02-16 | Boehringer Ingelheim Pharma GmbH & Co. KG | Regeneration of hydrolysis sensitive adsorbent matrices |
US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
US8026729B2 (en) | 2003-09-16 | 2011-09-27 | Cardiomems, Inc. | System and apparatus for in-vivo assessment of relative position of an implant |
US20050065760A1 (en) | 2003-09-23 | 2005-03-24 | Robert Murtfeldt | Method for advising patients concerning doses of insulin |
US7029456B2 (en) | 2003-10-15 | 2006-04-18 | Baxter International Inc. | Medical fluid therapy flow balancing and synchronization system |
EP1680155B2 (en) | 2003-10-28 | 2015-11-04 | Baxter International Inc. | Dialysis machine with improved integrity test |
ATE494022T1 (en) | 2003-10-31 | 2011-01-15 | Gambro Lundia Ab | CIRCUIT FOR EXTRACORPORAL BLOOD TREATMENT AND FLOW REVERSAL DEVICE USED |
US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
US7776006B2 (en) | 2003-11-05 | 2010-08-17 | Baxter International Inc. | Medical fluid pumping system having real time volume determination |
FR2862204B1 (en) | 2003-11-13 | 2006-02-10 | Yves Vincent Brottier | ELECTRIC DISCHARGE CLEANING APPARATUS IN A CURRENT FLASH LAMP |
EP1691862A1 (en) | 2003-11-20 | 2006-08-23 | Gambro Lundia AB | Method, apparatus and software program for measurement of a parameter relating to a heart-lung system of a mammal. |
US7744553B2 (en) | 2003-12-16 | 2010-06-29 | Baxter International Inc. | Medical fluid therapy flow control systems and methods |
JP4903583B2 (en) | 2003-12-24 | 2012-03-28 | ケミカ テクノロジーズ, インコーポレイテッド | Portable personal dialysis dialysate regeneration system |
DE102004013814A1 (en) | 2004-03-20 | 2005-10-13 | B. Braun Medizintechnologie Gmbh | A method of allowing operator input on a medical device |
US20050234354A1 (en) | 2004-04-15 | 2005-10-20 | Rowlandson G I | System and method for assessing a patient's risk of sudden cardiac death |
US7303540B2 (en) | 2004-04-26 | 2007-12-04 | Chf Solutions, Inc. | User interface for blood treatment device |
US7776210B2 (en) | 2004-06-09 | 2010-08-17 | Renal Solutions, Inc. | Dialysis system |
ITMO20040191A1 (en) | 2004-07-23 | 2004-10-23 | Gambro Lundia Ab | MACHINE AND METHOD FOR EXTRA-BODY BLOOD TREATMENT. |
US7356366B2 (en) | 2004-08-02 | 2008-04-08 | Cardiac Pacemakers, Inc. | Device for monitoring fluid status |
US7219596B2 (en) | 2004-08-19 | 2007-05-22 | Carrier Commerical Refrigeration, Inc. | Coffee brewer with loading and ejection mechanism for a coffee cartridge |
JP4868772B2 (en) | 2004-08-24 | 2012-02-01 | 日機装株式会社 | Blood purification equipment |
US7615028B2 (en) | 2004-12-03 | 2009-11-10 | Chf Solutions Inc. | Extracorporeal blood treatment and system having reversible blood pumps |
CN101090772A (en) | 2004-12-28 | 2007-12-19 | 雷纳尔溶液公司 | Method of synthesizing zirconium phosphate particles |
US7756572B1 (en) | 2005-01-25 | 2010-07-13 | Pacesetter, Inc. | System and method for efficiently distinguishing among cardiac ischemia, hypoglycemia and hyperglycemia using an implantable medical device and an external system |
WO2006086490A1 (en) | 2005-02-07 | 2006-08-17 | Medtronic, Inc. | Ion imbalance detector |
US20060189926A1 (en) | 2005-02-14 | 2006-08-24 | Hall W D | Apparatus and methods for analyzing body fluid samples |
US20060195064A1 (en) | 2005-02-28 | 2006-08-31 | Fresenius Medical Care Holdings, Inc. | Portable apparatus for peritoneal dialysis therapy |
JP4726045B2 (en) | 2005-04-08 | 2011-07-20 | 日機装株式会社 | Hemodialysis machine |
US7569050B2 (en) | 2005-05-06 | 2009-08-04 | Medtronic Minimed, Inc. | Infusion device and method with drive device in infusion device and method with drive device in separable durable housing portion |
EP1883434B1 (en) | 2005-05-06 | 2014-01-22 | Quanta Fluid Solutions Ltd | Fluid processing apparatus |
ES2348407T3 (en) | 2005-05-18 | 2010-12-03 | Gambro Lundia Ab | APPLIANCE TO CONTROL THE BLOOD FLOW IN AN EXTRACORPORE CIRCUIT. |
JP5189360B2 (en) | 2005-05-23 | 2013-04-24 | 旭化成メディカル株式会社 | Body fluid treatment filter device |
JP2007044602A (en) | 2005-08-09 | 2007-02-22 | Kanto Chem Co Inc | Catalyst carrier, metal fixed catalyst, production method thereof, and method for oxidizing alcohol using the same |
US7674231B2 (en) | 2005-08-22 | 2010-03-09 | Massachusetts Institute Of Technology | Wearable pulse wave velocity blood pressure sensor and methods of calibration thereof |
US8372025B2 (en) | 2005-09-22 | 2013-02-12 | Baxter International Inc. | Automation and optimization of CRRT treatment using regional citrate anticoagulation |
WO2007046186A1 (en) | 2005-10-18 | 2007-04-26 | Jms Co. Ltd. | Peritoneal membrane function test method, peritoneal membrane function test apparatus and peritoneal membrane function test program |
US20100137693A1 (en) | 2005-11-01 | 2010-06-03 | Fresenius Medical Care Holdings, Inc. | Methods and systems for patient care |
DE102005060866B4 (en) | 2005-12-20 | 2009-01-15 | Bruker Biospin Gmbh | Combined titration and pH electrode for the preparation of liquid samples, especially for NMR spectroscopy |
WO2007073500A2 (en) | 2005-12-22 | 2007-06-28 | E. I. Du Pont De Nemours And Company | Methods to prepare chemically stabilized ionomers containing inorganic fillers |
EP1979020A4 (en) | 2006-01-30 | 2011-03-30 | Univ California | Peritoneal dialysis methods and apparatus |
US8246563B2 (en) | 2006-02-02 | 2012-08-21 | Cardiac Pacemakers, Inc. | Cardiac rhythm management device and sensor-suite for the optimal control of ultrafiltration and renal replacement therapies |
WO2007101064A2 (en) | 2006-02-22 | 2007-09-07 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
US8012118B2 (en) | 2006-03-08 | 2011-09-06 | Fresenius Medical Care Holdings, Inc. | Artificial kidney dialysis system |
US8715221B2 (en) | 2006-03-08 | 2014-05-06 | Fresenius Medical Care Holdings, Inc. | Wearable kidney |
US7785463B2 (en) | 2006-03-17 | 2010-08-31 | Children's Hospital Medical Center | Extracorporeal renal replacement modeling system |
US20070243113A1 (en) | 2006-04-12 | 2007-10-18 | Dileo Anthony | Filter with memory, communication and concentration sensor |
CA3099207C (en) | 2006-04-14 | 2023-03-07 | Deka Products Limited Partnership | A flexible diaphragm for use in a reciprocating positive-displacement pump |
US8366316B2 (en) | 2006-04-14 | 2013-02-05 | Deka Products Limited Partnership | Sensor apparatus systems, devices and methods |
US7942844B2 (en) | 2006-04-28 | 2011-05-17 | Medtronic Minimed, Inc. | Remote monitoring for networked fluid infusion systems |
US8226595B2 (en) | 2006-05-26 | 2012-07-24 | Baxter International Inc. | Automated dialysis system driven by gravity and vacuum |
US7572232B2 (en) | 2006-07-24 | 2009-08-11 | Cardiac Pacemakers, Inc. | Cardiac signal display and event detection using multiresolution Z-score transform |
SE532971C2 (en) | 2006-08-16 | 2010-05-25 | Triomed Ab | Liquid regeneration system |
US7887502B2 (en) | 2006-09-15 | 2011-02-15 | University Of Florida Research Foundation, Inc. | Method for using photoplethysmography to optimize fluid removal during renal replacement therapy by hemodialysis or hemofiltration |
US8831717B2 (en) | 2006-09-19 | 2014-09-09 | Gambro Lundia Ab | Estimation of propensity to symptomatic hypotension |
GB0621452D0 (en) | 2006-10-27 | 2006-12-06 | Ucl Business Plc | Therapy for liver disease |
WO2008064174A1 (en) | 2006-11-17 | 2008-05-29 | National Quality Care, Inc. | Enhanced clearance in an artificial kidney incorporating a pulsatile pump |
CA2671010C (en) | 2006-12-01 | 2012-04-24 | Gambro Lundia Ab | Blood treatment apparatus |
US20110247973A1 (en) | 2006-12-08 | 2011-10-13 | Ohio University | Exfiltration apparatus |
EP2114510A4 (en) | 2006-12-19 | 2014-04-16 | Arnold J Lande | Chronic access system for extracorporeal treatment of blood including a continuously wearable hemodialyzer |
JP2010512939A (en) | 2006-12-21 | 2010-04-30 | ネーデルランド オルガニサティ フォール トウゲパストナチュールウェテンスカッペリューク オンデルツォイック ティーエヌオー | Device for removing toxic substances from blood |
US9968266B2 (en) | 2006-12-27 | 2018-05-15 | Cardiac Pacemakers, Inc. | Risk stratification based heart failure detection algorithm |
US20080161751A1 (en) | 2006-12-29 | 2008-07-03 | Plahey Kulwinder S | Peritoneal dialysis therapy validation |
US8183046B2 (en) | 2007-01-11 | 2012-05-22 | The Board Of Trustees Of The University Of Illinois | Temperature resistant pH buffers for use at low temperatures |
US8409441B2 (en) | 2007-02-27 | 2013-04-02 | Deka Products Limited Partnership | Blood treatment systems and methods |
US8042563B2 (en) | 2007-02-27 | 2011-10-25 | Deka Products Limited Partnership | Cassette system integrated apparatus |
US8357298B2 (en) | 2007-02-27 | 2013-01-22 | Deka Products Limited Partnership | Hemodialysis systems and methods |
MX357266B (en) | 2007-02-27 | 2018-07-03 | Deka Products Lp | Hemodialysis systems and methods. |
US20080253911A1 (en) | 2007-02-27 | 2008-10-16 | Deka Products Limited Partnership | Pumping Cassette |
US7906085B2 (en) | 2007-03-30 | 2011-03-15 | Battelle Memorial Institute | Fast-regenerable sulfur dioxide adsorbents for diesel engine emission control |
CN101678161B (en) | 2007-04-12 | 2012-11-07 | 甘布罗伦迪亚股份公司 | Method and apparatus for priming an extracorporeal blood circuit |
EP2142235B1 (en) | 2007-04-12 | 2012-03-21 | Gambro Lundia AB | Apparatus for extracorporeal blood treatment |
DE602007008544D1 (en) | 2007-06-20 | 2010-09-30 | Braun B Avitum Ag | Device for determining the reduction ratio or the Kt / V ratio of renal replacement therapy |
US7901376B2 (en) | 2007-07-05 | 2011-03-08 | Baxter International Inc. | Dialysis cassette having multiple outlet valve |
CN101541957B (en) | 2007-07-20 | 2013-08-14 | 梅约医学教育与研究基金会 | Natriuretic polypeptides |
US7981082B2 (en) | 2007-08-21 | 2011-07-19 | Hospira, Inc. | System and method for reducing air bubbles in a fluid delivery line |
AT505690B1 (en) | 2007-08-31 | 2012-09-15 | Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems | METHOD OF DETERMINING ION CONCENTRATION IN CITRATE ANTICOAGULATED EXTRACORPORAL BLOOD CLEANING |
US9199022B2 (en) | 2008-09-12 | 2015-12-01 | Fresenius Medical Care Holdings, Inc. | Modular reservoir assembly for a hemodialysis and hemofiltration system |
US8105487B2 (en) | 2007-09-25 | 2012-01-31 | Fresenius Medical Care Holdings, Inc. | Manifolds for use in conducting dialysis |
US20090101577A1 (en) | 2007-09-28 | 2009-04-23 | Fulkerson Barry N | Methods and Systems for Controlling Ultrafiltration Using Central Venous Pressure Measurements |
US8597505B2 (en) | 2007-09-13 | 2013-12-03 | Fresenius Medical Care Holdings, Inc. | Portable dialysis machine |
US20090084199A1 (en) | 2007-09-28 | 2009-04-02 | Wright James E | Quick-change sorbent trap module and method |
US7892331B2 (en) | 2007-10-01 | 2011-02-22 | Baxter International Inc. | Dialysis systems having air separation chambers with internal structures to enhance air removal |
US20090120864A1 (en) | 2007-10-05 | 2009-05-14 | Barry Neil Fulkerson | Wearable dialysis methods and devices |
US8771508B2 (en) | 2008-08-27 | 2014-07-08 | Deka Products Limited Partnership | Dialyzer cartridge mounting arrangement for a hemodialysis system |
US7905853B2 (en) | 2007-10-30 | 2011-03-15 | Baxter International Inc. | Dialysis system having integrated pneumatic manifold |
US9415150B2 (en) | 2007-11-09 | 2016-08-16 | Baxter Healthcare S.A. | Balanced flow dialysis machine |
CA2704011C (en) | 2007-11-16 | 2016-07-05 | Fresenius Medical Care Holdings, Inc. | Dialysis systems and methods |
US8889004B2 (en) | 2007-11-16 | 2014-11-18 | Fresenius Medical Care Holdings, Inc. | Dialysis systems and methods |
KR101369802B1 (en) | 2007-12-03 | 2014-03-04 | 헤파 바슈 게엠베하 | Dialysate regeneration unit |
EP2237851B1 (en) | 2008-01-18 | 2019-03-20 | Fresenius Medical Care Holdings, Inc. | Degassing device for carbon dioxide gas removal from a fluid circuit of a dialysis device |
JP5603255B2 (en) | 2008-01-23 | 2014-10-08 | デカ・プロダクツ・リミテッド・パートナーシップ | Fluid line automatic connection apparatus and method for medical treatment system |
US7687041B2 (en) | 2008-02-27 | 2010-03-30 | Kellogg Brown & Root Llc | Apparatus and methods for urea production |
US8019406B2 (en) | 2008-03-10 | 2011-09-13 | Biotronik Crm Patent Ag | Apparatus and method to assess the risk of R-on-T event |
JP2011515184A (en) | 2008-03-28 | 2011-05-19 | アランドラ メディカル, エセ.アー.ペー.イー.デー セー.ヴェー. | Liquid anesthetic cartridge and vaporizer |
CA2717890A1 (en) | 2008-04-30 | 2009-11-05 | Gambro Lundia Ab | Hydrophobic deaeration membrane |
US8882700B2 (en) | 2008-05-02 | 2014-11-11 | Baxter International Inc. | Smart patient transfer set for peritoneal dialysis |
US8233973B2 (en) | 2008-05-02 | 2012-07-31 | Spacelabs Healthcare, Llc | Methods for detection of cardiac arrhythmias |
US8220643B2 (en) | 2008-06-06 | 2012-07-17 | Fresenius Medical Care Holdings, Inc. | Urea sorbent |
EP2310069B1 (en) | 2008-06-23 | 2020-09-09 | Temasek Polytechnic | A flow system of a dialysis device and a portable dialysis device |
US9821105B2 (en) | 2008-07-01 | 2017-11-21 | Baxter International Inc. | Nanoclay sorbents for dialysis |
US8057679B2 (en) | 2008-07-09 | 2011-11-15 | Baxter International Inc. | Dialysis system having trending and alert generation |
JP5172508B2 (en) | 2008-07-09 | 2013-03-27 | 株式会社ジャパンディスプレイセントラル | Liquid crystal display |
US10265454B2 (en) | 2008-07-25 | 2019-04-23 | Baxter International Inc. | Dialysis system with flow regulation device |
US8696626B2 (en) | 2008-07-30 | 2014-04-15 | Claudia F. E. Kirsch | Debubbler |
AU2009285598B2 (en) | 2008-08-28 | 2015-07-02 | Deka Products Limited Partnership | Product dispensing system |
US20100051552A1 (en) | 2008-08-28 | 2010-03-04 | Baxter International Inc. | In-line sensors for dialysis applications |
EP2163272B1 (en) | 2008-09-15 | 2014-06-25 | B. Braun Avitum AG | Device to early predict the Kt/V parameter in kidney substitution treatments |
US8409444B2 (en) | 2008-09-30 | 2013-04-02 | Fresenius Medical Care Holdings, Inc. | Acid zirconium phosphate and alkaline hydrous zirconium oxide materials for sorbent dialysis |
CA3076044A1 (en) | 2008-09-30 | 2010-04-08 | Fresenius Medical Care Holdings, Inc. | Covalently immobilized enzyme and method to make the same |
CA2737071C (en) | 2008-10-03 | 2016-08-02 | Fresenius Medical Care Holdings, Inc. | Zirconium phosphate particles having improved adsorption capacity and method of synthesizing the same |
WO2010045474A2 (en) | 2008-10-16 | 2010-04-22 | Fresenius Medical Care Holdings, Inc. | Method of removing protein-bound deleterious substances during extracorporeal renal replacement treatment |
CN101725811A (en) | 2008-10-24 | 2010-06-09 | 鸿富锦精密工业(深圳)有限公司 | Supporting device |
US7927392B2 (en) | 2008-10-28 | 2011-04-19 | Bha Group, Inc. | Twist and lock connection for pleated filter element with flange-to-flange locking means |
JP5551709B2 (en) | 2008-11-03 | 2014-07-16 | フレゼニウス メディカル ケア ホールディングス インコーポレイテッド | Portable peritoneal dialysis system |
US8182673B2 (en) | 2009-01-29 | 2012-05-22 | Baxter International Inc. | Drain and fill logic for automated peritoneal dialysis |
WO2010088512A1 (en) | 2009-01-30 | 2010-08-05 | Baxter International Inc. | Transfer sets for therapy optimization |
MX346913B (en) | 2009-03-06 | 2017-04-05 | Baxter Int | Hemodialysis and peritoneal dialysis systems having electrodeionization capabilities. |
US20100312174A1 (en) | 2009-06-06 | 2010-12-09 | Hoffman Josef C A | Peritoneal Dialysis System |
US20100312172A1 (en) | 2009-06-06 | 2010-12-09 | Hoffman Josef C A | Method of Peritoneal Dialysis |
US8080161B2 (en) | 2009-06-11 | 2011-12-20 | Baxter International Inc. | Dialysis treatment devices for removing urea |
US9433356B2 (en) | 2009-06-26 | 2016-09-06 | Gambro Lundia Ab | Devices, a computer program product and a method for data extraction |
EP2449129B1 (en) | 2009-07-01 | 2014-04-16 | Board Of Regents, The University Of Texas System | Methods of determining the presence and/or concentration of an analyte in a sample |
US8180574B2 (en) | 2009-07-07 | 2012-05-15 | Baxter International | Simplified peritoneal equilibration test for peritoneal dialysis |
KR101642171B1 (en) | 2009-08-04 | 2016-07-22 | 프레제니우스 메디칼 케어 홀딩스 인코퍼레이티드 | Dialysis systems, components, and methods |
US8404091B2 (en) | 2009-08-27 | 2013-03-26 | Baxter International Inc. | Dialysis treatment devices for removing urea |
US20110066043A1 (en) | 2009-09-14 | 2011-03-17 | Matt Banet | System for measuring vital signs during hemodialysis |
US9399091B2 (en) | 2009-09-30 | 2016-07-26 | Medtronic, Inc. | System and method to regulate ultrafiltration |
US8518260B2 (en) | 2009-10-01 | 2013-08-27 | Fresenius Medical Care Holdings, Inc. | Method of controlling diffusive sodium transport in dialysis |
US20110130666A1 (en) | 2009-11-30 | 2011-06-02 | Yanting Dong | Enhanced reporting of pathological episodes |
CA2780883C (en) | 2009-12-07 | 2014-12-23 | Fresenius Medical Care Holdings, Inc. | Water purification cartridge using zirconium ion-exchange sorbents |
CA2785767A1 (en) | 2009-12-28 | 2011-07-07 | Gambro Lundia Ab | Apparatus and method for prediction of rapid symptomatic blood pressure decrease |
BR112012016793A2 (en) | 2010-01-08 | 2018-07-31 | Zafgen Corp | fumagilol-like compounds and methods of making and using them |
JP5442483B2 (en) | 2010-02-10 | 2014-03-12 | 日機装株式会社 | Blood purification equipment |
CN102190336B (en) | 2010-03-08 | 2014-11-26 | 周耀周 | Fluid treatment unit, fluid treatment component, and fluid treatment apparatus |
US8425780B2 (en) | 2010-03-11 | 2013-04-23 | Fresenius Medical Care Holdings, Inc. | Dialysis system venting devices and related systems and methods |
DE102010003642A1 (en) | 2010-03-15 | 2011-09-15 | Fresenius Medical Care Deutschland Gmbh | Cassette with a sensor for determining the difference between a first and a second liquid flow |
JP5548001B2 (en) | 2010-03-25 | 2014-07-16 | 日機装株式会社 | Blood purification equipment |
DE102010014785A1 (en) | 2010-04-13 | 2011-10-13 | Fresenius Medical Care Deutschland Gmbh | Multilayer film, use of a multilayer film and method for producing a multilayer film |
US9132219B2 (en) | 2010-04-16 | 2015-09-15 | Baxter International Inc. | Therapy prediction and optimization of serum potassium for renal failure blood therapy, especially home hemodialysis |
US20110272337A1 (en) | 2010-05-04 | 2011-11-10 | C-Tech Biomedical, Inc. | Dual mode hemodialysis machine |
WO2011140389A2 (en) | 2010-05-05 | 2011-11-10 | C-Tech Biomedical, Inc. | Membrane electrolyzer and hemodialysis system using the same |
DE102010020838A1 (en) | 2010-05-18 | 2011-11-24 | Fresenius Medical Care Deutschland Gmbh | Valve assembly for use in extracorporeal blood circulation and method |
US20110315632A1 (en) | 2010-05-24 | 2011-12-29 | Freije Iii William F | Membrane filtration system |
WO2011149730A2 (en) | 2010-05-24 | 2011-12-01 | Baxter International Inc. | Systems and methods for removing hydrogen peroxide from water purification systems |
DE102010023635A1 (en) | 2010-06-14 | 2011-12-15 | Fresenius Medical Care Deutschland Gmbh | Device and method for conveying liquids into the treatment unit of a medical treatment device, in particular into the dialyzer of a dialysis machine |
KR101862425B1 (en) | 2010-07-05 | 2018-05-29 | 감브로 룬디아 아베 | An ambulatory ultrafiltration device,related methods and a computer program product |
US8784668B2 (en) | 2010-10-12 | 2014-07-22 | Fresenius Medical Care Holdings, Inc. | Systems and methods for compensation of compliant behavior in regenerative dialysis systems |
DE102010042637A1 (en) | 2010-10-19 | 2012-04-19 | Endress + Hauser Conducta Gesellschaft für Mess- und Regeltechnik GmbH + Co. KG | conductivity sensor |
US8404491B2 (en) | 2010-10-29 | 2013-03-26 | Hewlett-Packard Development Company, L.P. | Luminescent chemical sensor integrated with at least one molecular trap |
EP2446908B1 (en) | 2010-11-02 | 2015-07-15 | ICinnovation BV | Electrosorption and decomposition device for the purification of blood and other fluids |
WO2012087798A2 (en) | 2010-12-20 | 2012-06-28 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
EP2678028A2 (en) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides |
US9161675B2 (en) | 2011-03-09 | 2015-10-20 | Bsh Home Appliances Corporation | Household appliance including information light device |
ITMI20110441A1 (en) | 2011-03-21 | 2012-09-22 | Gambro Lundia Ab | EQUIPMENT FOR EXTRACORPROUS TREATMENT OF BLOOD. |
US8945936B2 (en) | 2011-04-06 | 2015-02-03 | Fresenius Medical Care Holdings, Inc. | Measuring chemical properties of a sample fluid in dialysis systems |
WO2013012463A1 (en) | 2011-04-08 | 2013-01-24 | Life Technologies Corporation | AUTOMATED ON-INSTRUMENT pH ADJUSTMENT |
US9192707B2 (en) | 2011-04-29 | 2015-11-24 | Medtronic, Inc. | Electrolyte and pH monitoring for fluid removal processes |
US9848778B2 (en) | 2011-04-29 | 2017-12-26 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
US9456755B2 (en) | 2011-04-29 | 2016-10-04 | Medtronic, Inc. | Method and device to monitor patients with kidney disease |
WO2012148781A1 (en) | 2011-04-29 | 2012-11-01 | Medtronic, Inc. | Multimodal dialysis system |
US9132217B2 (en) | 2011-04-29 | 2015-09-15 | Medtronic, Inc. | Multimodal dialysis system |
EP2701580B1 (en) | 2011-04-29 | 2020-12-30 | Medtronic, Inc. | Device to monitor patients with kidney disease |
US9320842B2 (en) | 2011-04-29 | 2016-04-26 | Medtronic, Inc. | Multimodal dialysis system |
US20120303079A1 (en) | 2011-05-23 | 2012-11-29 | Deepa Mahajan | Apparatus and method for combined cardiac function management and renal therapies |
JP6239501B2 (en) | 2011-05-24 | 2017-11-29 | デカ・プロダクツ・リミテッド・パートナーシップ | Blood treatment system and method |
EP4074351A1 (en) | 2011-05-24 | 2022-10-19 | DEKA Products Limited Partnership | Hemodialysis system |
US20130019179A1 (en) | 2011-07-14 | 2013-01-17 | Digilink Software, Inc. | Mobile application enhancements |
CN103998371B (en) | 2011-07-26 | 2016-05-11 | 智能能源有限公司 | There is the hydrogen generator that improved fluid distributes |
DE102011052188A1 (en) | 2011-07-27 | 2013-01-31 | Maquet Vertrieb Und Service Deutschland Gmbh | Arrangement for removing carbon dioxide from blood flow or for enriching blood flow with oxygen, has filter, which has membrane, where membrane separates blood region, through which blood flow is guided |
US20130030356A1 (en) | 2011-07-29 | 2013-01-31 | Baxter Healthcare S.A. | Sodium management for dialysis systems |
DE102011108787A1 (en) | 2011-07-29 | 2013-01-31 | Fresenius Medical Care Deutschland Gmbh | Medical port, blood tube for use in extracorporeal blood treatment and medical treatment device |
KR101840088B1 (en) | 2011-07-29 | 2018-03-19 | 백스터 인터내셔널 인코포레이티드 | Sodium management for dialysis systems |
DE102011108786A1 (en) | 2011-07-29 | 2013-01-31 | Fresenius Medical Care Deutschland Gmbh | Method for determining at least one parameter of extracorporeal blood circulation and devices |
JP6001660B2 (en) | 2011-08-02 | 2016-10-05 | メドトロニック,インコーポレイテッド | Hemodialysis system having a flow path with controlled follow-up volume |
US20130037142A1 (en) | 2011-08-08 | 2013-02-14 | Fresenius Medical Care Holdings, Inc. | Dialysis system having peristaltic pump arrangement |
EP2727614A4 (en) | 2011-08-09 | 2015-03-18 | Kawasumi Lab Inc | Blood purifying system |
US10857277B2 (en) | 2011-08-16 | 2020-12-08 | Medtronic, Inc. | Modular hemodialysis system |
CA2844689C (en) | 2011-08-18 | 2016-04-12 | Harold F. Sandford | Sorbent and chemical regeneration of dialysate |
WO2013027214A2 (en) | 2011-08-22 | 2013-02-28 | Bar-Ilan University | Nanop article dialysis |
WO2013028809A2 (en) | 2011-08-22 | 2013-02-28 | Medtronic, Inc. | Dual flow sorbent cartridge |
EP3187212B1 (en) | 2011-08-30 | 2021-07-21 | Gambro Lundia AB | Apparatus for extracorporeal treatment of blood |
EP2564884B1 (en) | 2011-08-30 | 2014-06-18 | Gambro Lundia AB | Medical apparatus for extracorporeal treatment of fluid and a process of calculating set flow rates in a medical apparatus for delivery or collection of fluids |
DE102011053200A1 (en) | 2011-09-01 | 2013-03-07 | Fresenius Medical Care Deutschland Gmbh | Dialysate flow control |
EP2797684B1 (en) | 2011-12-29 | 2020-03-11 | Fresenius Medical Care Holdings, Inc. | Sorbent cartridge for dialysis |
US9616163B2 (en) | 2012-01-04 | 2017-04-11 | Fresenius Medical Care Holdings, Inc. | Method and system of enhancing removal of toxic anions and organic solutes in sorbent dialysis |
WO2013103906A1 (en) | 2012-01-04 | 2013-07-11 | Medtronic, Inc. | Multi-staged filtration system for blood fluid removal |
BR112014017681A8 (en) | 2012-01-19 | 2017-07-11 | Baxter Int | METHOD AND COMPOSITION FOR THE REMOVAL OF UREMIC TOXINS IN DIALYSIS PROCESSES |
WO2013114063A1 (en) | 2012-02-02 | 2013-08-08 | Quanta Fluid Solutions Ltd. | Dialysis machine |
US9682183B2 (en) | 2012-02-14 | 2017-06-20 | Quanta Fluid Solutions Ltd. | Dialysis machine |
JP5629714B2 (en) | 2012-03-19 | 2014-11-26 | トヨタ自動車株式会社 | Semiconductor device |
US9610392B2 (en) | 2012-06-08 | 2017-04-04 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
US9500188B2 (en) | 2012-06-11 | 2016-11-22 | Fresenius Medical Care Holdings, Inc. | Medical fluid cassettes and related systems and methods |
US9231692B2 (en) | 2012-09-04 | 2016-01-05 | Viasat Inc. | Paired-beam transponder satellite communication |
US9138520B2 (en) | 2012-10-22 | 2015-09-22 | Baxter International Inc. | Total chlorine water detection system and method for medical fluid treatments |
US9162021B2 (en) | 2012-10-22 | 2015-10-20 | Baxter International Inc. | Integrated water testing system and method for ultra-low total chlorine detection |
JP2014097224A (en) | 2012-11-15 | 2014-05-29 | Tatsunori Kato | Dialysis unit and method for measuring access recirculation rate |
US10905816B2 (en) | 2012-12-10 | 2021-02-02 | Medtronic, Inc. | Sodium management system for hemodialysis |
US9399090B2 (en) | 2012-12-10 | 2016-07-26 | Medtronic, Inc. | Potassium loaded ion-exchange material for use in a dialysate regeneration system |
US20140158588A1 (en) | 2012-12-10 | 2014-06-12 | Medtronic, Inc. | pH AND BUFFER MANAGEMENT SYSTEM FOR HEMODIALYSIS SYSTEMS |
US11565029B2 (en) | 2013-01-09 | 2023-01-31 | Medtronic, Inc. | Sorbent cartridge with electrodes |
US11154648B2 (en) | 2013-01-09 | 2021-10-26 | Medtronic, Inc. | Fluid circuits for sorbent cartridge with sensors |
US9713666B2 (en) | 2013-01-09 | 2017-07-25 | Medtronic, Inc. | Recirculating dialysate fluid circuit for blood measurement |
US9707328B2 (en) * | 2013-01-09 | 2017-07-18 | Medtronic, Inc. | Sorbent cartridge to measure solute concentrations |
WO2014121162A1 (en) | 2013-02-01 | 2014-08-07 | Medtronic, Inc. | Sorbent cartridge to measure solute concentrations |
US9526822B2 (en) | 2013-02-01 | 2016-12-27 | Medtronic, Inc. | Sodium and buffer source cartridges for use in a modular controlled compliant flow path |
US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
US9827361B2 (en) | 2013-02-02 | 2017-11-28 | Medtronic, Inc. | pH buffer measurement system for hemodialysis systems |
WO2014151274A1 (en) | 2013-03-14 | 2014-09-25 | Longhenry Daniel Paul | System and method for generating and dispensing sodium hydroxide solutions |
US20150057602A1 (en) | 2013-08-26 | 2015-02-26 | Roger Alan Mason | System and Method for Administering Peritoneal Dialysis |
US10159957B2 (en) * | 2013-11-26 | 2018-12-25 | Medtronic, Inc. | Zirconium phosphate recharging customization |
US9943780B2 (en) | 2013-11-26 | 2018-04-17 | Medtronic, Inc. | Module for in-line recharging of sorbent materials with optional bypass |
US10052612B2 (en) * | 2013-11-26 | 2018-08-21 | Medtronic, Inc. | Zirconium phosphate recharging method and apparatus |
US9884145B2 (en) | 2013-11-26 | 2018-02-06 | Medtronic, Inc. | Parallel modules for in-line recharging of sorbents using alternate duty cycles |
US9895477B2 (en) | 2013-11-26 | 2018-02-20 | Medtronic, Inc. | Detachable module for recharging sorbent materials with optional bypass |
US9981245B2 (en) | 2013-11-26 | 2018-05-29 | Medtronic, Inc. | Method and apparatus for zirconium oxide recharging |
US10064986B2 (en) | 2013-11-26 | 2018-09-04 | Medtronic, Inc. | Recharger for recharging zirconium phosphate and zirconium oxide modules |
US10537875B2 (en) | 2013-11-26 | 2020-01-21 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
US10004839B2 (en) | 2013-11-26 | 2018-06-26 | Medtronic, Inc. | Multi-use sorbent cartridge |
US10099214B2 (en) | 2013-11-26 | 2018-10-16 | Medtronic, Inc. | Zirconium phosphate and zirconium oxide recharger control logic and operational process algorithms |
JP6438042B2 (en) | 2014-02-19 | 2018-12-12 | メドトロニック,インコーポレイテッド | Module for refilling adsorbent material inline with optional bypass |
US9764073B2 (en) | 2014-02-26 | 2017-09-19 | Medtronic, Inc. | Authentication and tracking system |
BR112016014853B1 (en) | 2014-03-17 | 2022-05-24 | Fresenius Medical Care Holdings, Inc | Adsorbent cartridge, method for regenerating or purifying dialysis fluid, dialysis system for regenerating or purifying used dialysis fluid, and method of manufacturing an adsorbent cartridge |
US10172991B2 (en) | 2014-06-24 | 2019-01-08 | Medtronic, Inc. | Modular dialysate regeneration assembly |
EP3160534A4 (en) | 2014-06-24 | 2018-03-07 | Medtronic Inc. | Stacked sorbent assembly |
US10286380B2 (en) | 2014-06-24 | 2019-05-14 | Medtronic, Inc. | Sorbent pouch |
WO2015199764A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Replenishing urease in dialysis systems using urease pouches |
WO2015199760A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | Replenisihing urease in dialysis systems using a urease introducer |
EP3160536A4 (en) | 2014-06-24 | 2018-03-07 | Medtronic Inc. | Reserve zirconium phosphate module for use in sorbent dialysis |
WO2015199763A1 (en) | 2014-06-24 | 2015-12-30 | Medtronic, Inc. | A urease introduction system for replenishing urease in a sorbent cartridge |
WO2016191041A1 (en) | 2015-05-26 | 2016-12-01 | Medtronic, Inc. | Zirconium phosphate and zirconium oxide recharging flow paths |
WO2016191039A1 (en) | 2015-05-26 | 2016-12-01 | Medtronic, Inc. | Recharger for recharging zirconium phosphate and zirconium oxide modules |
FR3037830B1 (en) | 2015-06-29 | 2024-02-16 | Snecma | MOLDING ASSEMBLY FOR A TURBOMACHINE BLADE, INCLUDING A LARGE SECTION RELIEF PORTION |
EP3546042A1 (en) | 2018-03-30 | 2019-10-02 | Medtronic, Inc. | Precision recharging of sorbent materials using patient and session data |
US20200086297A1 (en) | 2018-09-19 | 2020-03-19 | Medtronic, Inc. | Precision recharging based on sorbent effluent analysis |
-
2018
- 2018-04-20 US US15/958,337 patent/US10960381B2/en active Active
- 2018-06-11 CN CN201810596909.6A patent/CN109126682A/en active Pending
- 2018-06-14 EP EP18177673.3A patent/EP3415182B1/en active Active
-
2021
- 2021-02-25 US US17/185,604 patent/US11883794B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150108069A1 (en) * | 2013-10-23 | 2015-04-23 | Fresenius Medical Care Holdings, Inc. | Process For Regeneration Of Spent Zirconium Phosphate For Reuse in Sorbent Treatments |
US20160236188A1 (en) * | 2013-11-26 | 2016-08-18 | Medtronic, Inc. | MANAGEMENT OF RECHARGER EFFLUENT pH |
US20160243541A1 (en) * | 2013-11-26 | 2016-08-25 | Medtronic, Inc. | Zirconium phosphate and zirconium oxide recharging flow paths |
US20150367055A1 (en) * | 2014-06-24 | 2015-12-24 | Medtronic, Inc. | Method of zirconium phosphate recharging |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020113066A1 (en) * | 2018-11-28 | 2020-06-04 | Baxter International Inc. | Systems and methods for onsite sorbent material reuse |
WO2020113069A1 (en) * | 2018-11-28 | 2020-06-04 | Baxter International Inc. | Systems and methods for batch sorbent material reuse |
US11090421B2 (en) | 2018-11-28 | 2021-08-17 | Baxter International Inc. | Systems and methods for batch sorbent material reuse |
US11253849B2 (en) | 2018-11-28 | 2022-02-22 | Baxter International Inc. | Systems and methods for onsite sorbent material reuse |
US11833284B2 (en) | 2018-11-28 | 2023-12-05 | Baxter International Inc. | Systems and methods for batch sorbent material reuse |
US11925916B2 (en) | 2018-11-28 | 2024-03-12 | Baxter International Inc. | Method and composition for removing uremic toxins |
Also Published As
Publication number | Publication date |
---|---|
EP3415182B1 (en) | 2022-05-04 |
US10960381B2 (en) | 2021-03-30 |
US11883794B2 (en) | 2024-01-30 |
CN109126682A (en) | 2019-01-04 |
US20180361354A1 (en) | 2018-12-20 |
US20210178365A1 (en) | 2021-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11883794B2 (en) | Zirconium phosphate disinfection recharging and conditioning | |
EP3302609B1 (en) | Recharger for recharging zirconium phosphate and zirconium oxide modules | |
US10064986B2 (en) | Recharger for recharging zirconium phosphate and zirconium oxide modules | |
US20170281847A1 (en) | Regenerative peritoneal dialysis system | |
US10099215B2 (en) | Management of recharger effluent pH | |
US10099214B2 (en) | Zirconium phosphate and zirconium oxide recharger control logic and operational process algorithms | |
CN108159733B (en) | Zirconia module conditioning | |
EP3302610B1 (en) | Zirconium phosphate and zirconium oxide recharging flow paths | |
US10159957B2 (en) | Zirconium phosphate recharging customization | |
EP3326712B1 (en) | Zirconium phosphate recharging customization | |
US11213616B2 (en) | Recharge solution for zirconium phosphate | |
US20220226552A1 (en) | Automatic recharger brine preparation from a salt cartridge | |
EP3415183A2 (en) | Zirconium oxide disinfection recharging and conditioning | |
CN107660161B (en) | Recharger effluent pH management | |
EP3623042B1 (en) | Recharge solution for zirconium oxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190618 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: B01J 20/34 20060101ALI20211104BHEP Ipc: B01J 20/02 20060101ALI20211104BHEP Ipc: A61M 1/16 20060101AFI20211104BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20211217 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HOBOT, CHRISTOPHER M. Inventor name: PUDIL, BRYANT |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1488344 Country of ref document: AT Kind code of ref document: T Effective date: 20220515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Ref country code: DE Ref legal event code: R096 Ref document number: 602018034797 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20220504 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1488344 Country of ref document: AT Kind code of ref document: T Effective date: 20220504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220905 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220804 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220805 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220804 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018034797 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
26N | No opposition filed |
Effective date: 20230207 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20220804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220614 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220614 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220704 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220804 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20180614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220504 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240521 Year of fee payment: 7 |